VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q6766473 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241221010851.0
008 241221nneanz||abbn n and d
035 ‎‡a (WKP)Q6766473‏
024 ‎‡a 0000-0002-3739-4459‏ ‎‡2 orcid‏
024 ‎‡a 55574203004‏ ‎‡2 scopus‏
035 ‎‡a (OCoLC)Q6766473‏
043 ‎‡c US‏
046 ‎‡f 19650815‏ ‎‡g 20101219‏
100 0 ‎‡a Mark Anthony Smith‏ ‎‡c American neuroscientist and Alzheimer researcher (1965-2010)‏ ‎‡9 en‏
375 ‎‡a 1‏ ‎‡2 iso5218‏
400 0 ‎‡a Mark Smith‏ ‎‡9 sco‏ ‎‡9 scn‏ ‎‡9 co‏ ‎‡9 io‏ ‎‡9 pms‏ ‎‡9 vmf‏ ‎‡9 mi‏ ‎‡9 sr-el‏ ‎‡9 an‏ ‎‡9 cs‏ ‎‡9 cy‏ ‎‡9 gd‏ ‎‡9 ga‏ ‎‡9 et‏ ‎‡9 eu‏ ‎‡9 zu‏ ‎‡9 gl‏ ‎‡9 ie‏ ‎‡9 id‏ ‎‡9 prg‏ ‎‡9 en-gb‏ ‎‡9 lb‏ ‎‡9 nrm‏ ‎‡9 nn‏ ‎‡9 min‏ ‎‡9 frp‏ ‎‡9 af‏ ‎‡9 nap‏ ‎‡9 lij‏ ‎‡9 li‏ ‎‡9 hr‏ ‎‡9 lt‏ ‎‡9 jam‏ ‎‡9 vec‏ ‎‡9 nds-nl‏ ‎‡9 vi‏ ‎‡9 rm‏ ‎‡9 ro‏ ‎‡9 ia‏ ‎‡9 pcd‏ ‎‡9 frc‏ ‎‡9 kab‏ ‎‡9 wa‏ ‎‡9 wo‏ ‎‡9 bm‏ ‎‡9 hu‏ ‎‡9 sc‏ ‎‡9 br‏ ‎‡9 fur‏ ‎‡9 vls‏ ‎‡9 vo‏ ‎‡9 kg‏ ‎‡9 en-ca‏ ‎‡9 mg‏ ‎‡9 bar‏ ‎‡9 gsw‏ ‎‡9 oc‏ ‎‡9 sv‏ ‎‡9 de-ch‏ ‎‡9 sk‏ ‎‡9 pap‏ ‎‡9 pl‏ ‎‡9 ms‏ ‎‡9 de-at‏ ‎‡9 nds‏ ‎‡9 rgn‏ ‎‡9 sw‏
400 0 ‎‡a Mark A. Smith‏ ‎‡9 fr‏ ‎‡9 pt‏ ‎‡9 ca‏ ‎‡9 de‏ ‎‡9 it‏ ‎‡9 da‏ ‎‡9 pt-br‏ ‎‡9 sl‏ ‎‡9 fi‏ ‎‡9 nb‏
400 0 ‎‡a Mark Smith‏ ‎‡c araştırmacı‏ ‎‡9 tr‏
400 0 ‎‡a Mark Smith‏ ‎‡c usona neŭrosciencisto‏ ‎‡9 eo‏
400 0 ‎‡a Mark A. Smith‏ ‎‡c neurocientífico estadounidense‏ ‎‡9 es‏
400 0 ‎‡a Mark A. Smith‏ ‎‡c neurocientíficu estauxunidense (1965–2010)‏ ‎‡9 ast‏
400 0 ‎‡a মার্ক এ. স্মিথ‏ ‎‡9 bn‏
400 0 ‎‡a مارك سميث‏ ‎‡c عالم أعصاب من الولايات المتحدة الأمريكية‏ ‎‡9 ar‏
400 0 ‎‡a Mark A. Smith‏ ‎‡c Amerikaans neurowetenschapper (1965-2010)‏ ‎‡9 nl‏
400 0 ‎‡a مارک ای. اسمیت‏ ‎‡9 fa‏
670 ‎‡a Author's 4-Oxo-2-nonenal is both more neurotoxic and more protein reactive than 4-hydroxy-2-nonenal‏
670 ‎‡a Author's A clinical study of lupron depot in the treatment of women with Alzheimer's disease: preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose lupron over 48 weeks‏
670 ‎‡a Author's A metabolic basis for Alzheimer disease‏
670 ‎‡a Author's A new model of oxidative stress in rat pups‏
670 ‎‡a Author's A novel approach to the identification and quantitative elemental analysis of amyloid deposits--insights into the pathology of Alzheimer's disease‏
670 ‎‡a Author's A novel endogenous indole protects rodent mitochondria and extends rotifer lifespan‏
670 ‎‡a Author's A novel origin for granulovacuolar degeneration in aging and Alzheimer's disease: parallels to stress granules‏
670 ‎‡a Author's A second look into the oxidant mechanisms in Alzheimer's disease‏
670 ‎‡a Author's A synergistic dysfunction of mitochondrial fission/fusion dynamics and mitophagy in Alzheimer's disease‏
670 ‎‡a Author's Aberrant expression of metabotropic glutamate receptor 2 in the vulnerable neurons of Alzheimer's disease‏
670 ‎‡a Author's Aberrant localization of importin Alpha 1 in hippocampal neurons in Alzheimer disease‏
670 ‎‡a Author's Abnormal iron metabolism and oxidative stress in mice expressing a mutant form of the ferritin light polypeptide gene‏
670 ‎‡a Author's Abnormal mitochondrial dynamics--a novel therapeutic target for Alzheimer's disease?‏
670 ‎‡a Author's Abnormal mitochondrial dynamics and neurodegenerative diseases‏
670 ‎‡a Author's Abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease‏
670 ‎‡a Author's Absence of cellular stress in brain after hypoxia induced by arousal from hibernation in Arctic ground squirrels‏
670 ‎‡a Author's Accelerated Alpha -synuclein aggregation after differentiation of SH-SY5Y neuroblastoma cells‏
670 ‎‡a Author's Accumulation of intraneuronal amyloid-β is common in normal brain.‏
670 ‎‡a Author's Activation of Akt by lithium: pro-survival pathways in aging‏
670 ‎‡a Author's Activation of P38 kinase links π phosphorylation, oxidative stress and cell cycle-related events in Alzheimer disease‏
670 ‎‡a Author's Activation of the extracellular signal-regulated kinase pathway contributes to the behavioral deficit of fragile x-syndrome‏
670 ‎‡a Author's Adventiously-bound redox active iron and copper are at the center of oxidative damage in Alzheimer disease‏
670 ‎‡a Author's AGEs/RAGE complex upregulates BACE1 via NF-κB pathway activation‏
670 ‎‡a Author's All-trans retinoic acid as a novel therapeutic strategy for Alzheimer's disease‏
670 ‎‡a Author's Altered redox balance in disease: Can we change the new equilibria?‏
670 ‎‡a Author's Alzheimer disease and the role of free radicals in the pathogenesis of the disease‏
670 ‎‡a Author's Alzheimer disease: evidence for a central pathogenic role of iron-mediated reactive oxygen species‏
670 ‎‡a Author's Alzheimer Disease: Oxidative Stress and Compensatory Responses‏
670 ‎‡a Author's Alzheimer disease pathology as a host response‏
670 ‎‡a Author's Alzheimer disease, the two-hit hypothesis: an update‏
670 ‎‡a Author's Alzheimer-specific epitopes of tau represent lipid peroxidation-induced conformations‏
670 ‎‡a Author's Alzheimer's Disease: Advances for a New Century‏
670 ‎‡a Author's Alzheimer's disease: an intracellular movement disorder?‏
670 ‎‡a Author's Alzheimers Disease and Oxidative Stress: The Old Problem Remains Unsolved‏
670 ‎‡a Author's Alzheimer's disease and the cell cycle‏
670 ‎‡a Author's Alzheimer's disease: cerebrovascular dysfunction, oxidative stress, and advanced clinical therapies‏
670 ‎‡a Author's Alzheimer's disease: diverse aspects of mitochondrial malfunctioning‏
670 ‎‡a Author's Alzheimer's disease: the two-hit hypothesis‏
670 ‎‡a Author's Amyloid-beta: a‏
670 ‎‡a Author's Amyloid-beta: a (life) preserver for the brain‏
670 ‎‡a Author's Amyloid-beta: a vascular sealant that protects against hemorrhage?‏
670 ‎‡a Author's Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain‏
670 ‎‡a Author's Amyloid-beta-derived diffusible ligands cause impaired axonal transport of mitochondria in neurons‏
670 ‎‡a Author's Amyloid-beta in Alzheimer's disease: the horse or the cart? Pathogenic or protective?‏
670 ‎‡a Author's Amyloid-beta-induced toxicity of primary neurons is dependent upon differentiation-associated increases in tau and cyclin-dependent kinase 5 expression.‏
670 ‎‡a Author's Amyloid-beta, tau alterations and mitochondrial dysfunction in Alzheimer disease: the chickens or the eggs?‏
670 ‎‡a Author's Amyloid beta: the alternate hypothesis‏
670 ‎‡a Author's Amyloid-beta vaccination: testing the amyloid hypothesis?: heads we win, tails you lose!‏
670 ‎‡a Author's Amyloid-beta42 interacts mainly with insoluble prion protein in the Alzheimer brain‏
670 ‎‡a Author's Amyloid-β42 Interacts Mainly with Insoluble Prion Protein in the Alzheimer Brain‏
670 ‎‡a Author's Amyloids, Aggregates and Neuronal Inclusions: Good or Bad News for Neurons?‏
670 ‎‡a Author's Amyotrophic lateral sclerosis: a novel hypothesis involving a gained 'loss of function' in the JNK/SAPK pathway‏
670 ‎‡a Author's Antibodies to potato virus Y bind the amyloid beta peptide: immunohistochemical and NMR studies‏
670 ‎‡a Author's Antigen-antibody dissociation in Alzheimer disease: a novel approach to diagnosis‏
670 ‎‡a Author's Antigonadotropins: a novel strategy to halt Alzheimer's disease progression‏
670 ‎‡a Author's Antimicrobial peptide β-defensin-1 expression is upregulated in Alzheimer's brain‏
670 ‎‡a Author's Antioxidant approaches for the treatment of Alzheimer's disease‏
670 ‎‡a Author's Antioxidant protection and neurodegenerative disease: the role of amyloid-beta and tau.‏
670 ‎‡a Author's Antioxidant therapy in Alzheimer's disease: theory and practice‏
670 ‎‡a Author's Apoptosis in Alzheimer disease: a mathematical improbability‏
670 ‎‡a Author's Apoptotic and Oxidative Indicators in Alzheimer's Disease‏
670 ‎‡a Author's Apoptotic promoters and inhibitors in Alzheimer's disease: Who wins out?‏
670 ‎‡a Author's Ascorbate distribution during hibernation is independent of ascorbate redox state‏
670 ‎‡a Author's Assembly in vitro of tau protein and its implications in Alzheimer's disease.‏
670 ‎‡a Author's Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels: implication in the pathogenesis of Alzheimer's disease‏
670 ‎‡a Author's Autophagocytosis of mitochondria is prominent in Alzheimer disease‏
670 ‎‡a Author's Autophagy in Alzheimer's disease‏
670 ‎‡a Author's Beyond estrogen: targeting gonadotropin hormones in the treatment of Alzheimer's disease‏
670 ‎‡a Author's Biomarkers in Alzheimer's disease: past, present and future‏
670 ‎‡a Author's BRCA1 may modulate neuronal cell cycle re-entry in Alzheimer disease‏
670 ‎‡a Author's c-Jun phosphorylation in Alzheimer disease‏
670 ‎‡a Author's Call for Elan to publish Alzheimer's trial details.‏
670 ‎‡a Author's Carnosine: a versatile antioxidant and antiglycating agent‏
670 ‎‡a Author's Causes versus effects: the increasing complexities of Alzheimer's disease pathogenesis‏
670 ‎‡a Author's CD3 in Lewy pathology: does the abnormal recall of neurodevelopmental processes underlie Parkinson's disease‏
670 ‎‡a Author's Cdk5 is a major regulator of p38 cascade: relevance to neurotoxicity in Alzheimer's disease‏
670 ‎‡a Author's Cell cycle deregulation in the neurons of Alzheimer's disease‏
670 ‎‡a Author's Cell cycle proteins in Alzheimer's disease: plenty of wheels but no cycle.‏
670 ‎‡a Author's Cell cycle re-entry and mitochondrial defects in myc-mediated hypertrophic cardiomyopathy and heart failure‏
670 ‎‡a Author's Cell cycle re-entry mediated neurodegeneration and its treatment role in the pathogenesis of Alzheimer's disease‏
670 ‎‡a Author's Cellular prion protein is essential for oligomeric amyloid-β-induced neuronal cell death‏
670 ‎‡a Author's Cerebral amyloid angiopathy: major contributor or decorative response to Alzheimer's disease pathogenesis‏
670 ‎‡a Author's Cerebral hemorrhage and amyloid-beta‏
670 ‎‡a Author's Cerebrotendinous xanthomatosis: case report with evidence of oxidative stress‏
670 ‎‡a Author's Challenging the amyloid cascade hypothesis: senile plaques and amyloid-beta as protective adaptations to Alzheimer disease‏
670 ‎‡a Author's Chapter 19. Targeting Oxidative Mechanisms in Alzheimer Disease‏
670 ‎‡a Author's Chapter 5 - Development of iron chelator-nanoparticle conjugates as potential therapeutic agents for Alzheimer disease‏
670 ‎‡a Author's Chitin-like polysaccharides in Alzheimer's disease brains‏
670 ‎‡a Author's Cholesterol homeostasis markers are localized to mouse hippocampal pyramidal and granule layers‏
670 ‎‡a Author's Cholesterol, oxidative stress, and Alzheimer's disease: expanding the horizons of pathogenesis‏
670 ‎‡a Author's Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer's disease‏
670 ‎‡a Author's Chronic Leptin Supplementation Ameliorates Pathology and Improves Cognitive Performance in a Transgenic Mouse Model of Alzheimer's Disease‏
670 ‎‡a Author's Chronic oxidative stress causes increased tau phosphorylation in M17 neuroblastoma cells‏
670 ‎‡a Author's Chronological primacy of oxidative stress in Alzheimer disease.‏
670 ‎‡a Author's Cleavage and conformational changes of tau protein follow phosphorylation during Alzheimer's disease‏
670 ‎‡a Author's Clinical benefit and preservation of flavonols in dark chocolate manufacturing‏
670 ‎‡a Author's Clusterin up-regulation following sub-lethal oxidative stress and lipid peroxidation in human neuroblastoma cells‏
670 ‎‡a Author's Commentary: "Ceramide and cholesterol: possible connections between normal aging of the brain and Alzheimer's disease. Just hypotheses or molecular pathways to be identified?" by Claudio Costantini, Rekha M.K. Kolasani, and Luigi Puglielli.‏
670 ‎‡a Author's Comparative biology and pathology of oxidative stress in Alzheimer and other neurodegenerative diseases: beyond damage and response‏
670 ‎‡a Author's Compensatory responses induced by oxidative stress in Alzheimer disease‏
670 ‎‡a Author's Contribution of redox-active iron and copper to oxidative damage in Alzheimer disease‏
670 ‎‡a Author's Copper Induces Apoptosis of Neuroblastoma Cells Via Post-translational Regulation of the Expression of Bcl-2-family Proteins and the tx Mouse is a Better Model of Hepatic than Brain Cu Toxicity‏
670 ‎‡a Author's Copper mediates dityrosine cross-linking of Alzheimer's amyloid-beta‏
670 ‎‡a Author's Current approaches in the treatment of Alzheimer's disease‏
670 ‎‡a Author's Decline in mitochondrial bioenergetics underlies central insulin resistance in streptozocin-induced model of sporadic Alzheimer's disease‏
670 ‎‡a Author's Dementia and testosterone levels in men.‏
670 ‎‡a Author's Detection and localization of markers of oxidative stress by in situ methods: application in the study of Alzheimer disease‏
670 ‎‡a Author's Differential regulation of glutamate receptors in Alzheimer's disease‏
670 ‎‡a Author's Direct and indirect roles of cyclin-dependent kinase 5 as an upstream regulator in the c-Jun NH2-terminal kinase cascade: relevance to neurotoxic insults in Alzheimer's disease‏
670 ‎‡a Author's Dissociated amyloid-beta antibody levels as a serum biomarker for the progression of Alzheimer's disease: a population-based study‏
670 ‎‡a Author's Dissociated Aβ antibody level in newly diagnosed Alzheimer's disease: A population-based study‏
670 ‎‡a Author's Disturbance in AMP-activated protein kinase‏
670 ‎‡a Author's Disturbance in AMP-activated protein kinase (AMPK) signaling pathway in Alzheimer's disease‏
670 ‎‡a Author's Divalent metal transporter, iron, and Parkinson's disease: a pathological relationship.‏
670 ‎‡a Author's DLP1-dependent mitochondrial fragmentation mediates 1-methyl-4-phenylpyridinium toxicity in neurons: implications for Parkinson's disease‏
670 ‎‡a Author's DNA damage induces cdk2 protein levels and histone H2B phosphorylation in SH-SY5Y neuroblastoma cells.‏
670 ‎‡a Author's Down-regulation of aminolevulinate synthase, the rate-limiting enzyme for heme biosynthesis in Alzheimer's disease‏
670 ‎‡a Author's Down-regulation of serum gonadotropins but not estrogen replacement improves cognition in aged-ovariectomized 3xTg AD female mice‏
670 ‎‡a Author's Down-regulation of serum gonadotropins is as effective as estrogen replacement at improving menopause-associated cognitive deficits‏
670 ‎‡a Author's Drug discovery for neurodegenerative diseases: challenges and novel biochemical targets dedicated to the memory of Mark A. Smith for his inspiring contribution to Alzheimer's disease‏
670 ‎‡a Author's Dysregulation of leptin signaling in Alzheimer disease: evidence for neuronal leptin resistance‏
670 ‎‡a Author's Dysregulation of the hypothalamic-pituitary-gonadal axis with menopause and andropause promotes neurodegenerative senescence‏
670 ‎‡a Author's Early amyloid accumulation in the hippocampus of SAMP8 mice‏
670 ‎‡a Author's Early induction of c-Myc is associated with neuronal cell death‏
670 ‎‡a Author's Early induction of oxidative stress in mouse model of Alzheimer disease with reduced mitochondrial superoxide dismutase activity‏
670 ‎‡a Author's Ectopic expression of phospho-Smad2 in Alzheimer's disease: uncoupling of the transforming growth factor-beta pathway?‏
670 ‎‡a Author's Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson's disease‏
670 ‎‡a Author's Ectopic localization of phosphorylated histone H3 in Alzheimer's disease: a mitotic catastrophe?‏
670 ‎‡a Author's Effect of quinones on microtubule polymerization: a link between oxidative stress and cytoskeletal alterations in Alzheimer's disease‏
670 ‎‡a Author's Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells‏
670 ‎‡a Author's Elevated expression of a regulator of the G2/M phase of the cell cycle, neuronal CIP-1-associated regulator of cyclin B, in Alzheimer's disease‏
670 ‎‡a Author's Elevated luteinizing hormone expression colocalizes with neurons vulnerable to Alzheimer's disease pathology‏
670 ‎‡a Author's Elevation of {beta}-amyloid 1-42 autoantibodies in the blood of amnestic patients with mild cognitive impairment‏
670 ‎‡a Author's Emerging evidence for the neuroprotective role of Alpha -synuclein‏
670 ‎‡a Author's Estrogen bows to a new master: the role of gonadotropins in Alzheimer pathogenesis‏
670 ‎‡a Author's Evidence for Oxidative Damage in the Autistic Brain‏
670 ‎‡a Author's Evidence for the novel expression of human kallikrein-related peptidase 3, prostate-specific antigen, in the brain.‏
670 ‎‡a Author's Evidence for the progression through S-phase in the ectopic cell cycle re-entry of neurons in Alzheimer disease‏
670 ‎‡a Author's Evidence for the role of luteinizing hormone in Alzheimer disease‏
670 ‎‡a Author's Evidence of DNA damage in Alzheimer disease: phosphorylation of histone H2AX in astrocytes‏
670 ‎‡a Author's Expression of CD74 is increased in neurofibrillary tangles in Alzheimer's disease‏
670 ‎‡a Author's Feedback on a feedback loop: the hypothalamic-pituitary-gonadal axis.‏
670 ‎‡a Author's Ferric cycle activity and Alzheimer disease‏
670 ‎‡a Author's Food Antioxidants and Alzheimer’s Disease‏
670 ‎‡a Author's Foreword: Apoptotic Mechanisms in Neurodegenerative Diseases‏
670 ‎‡a Author's Formation of aberrant phosphotau fibrillar polymers in neural cultured cells‏
670 ‎‡a Author's From aging to Alzheimer's disease: unveiling "the switch" with the senescence-accelerated mouse model‏
670 ‎‡a Author's From aging to Alzheimer's disease: unveiling "the switch" with the senescence-accelerated mouse model (SAMP8).‏
670 ‎‡a Author's Frontiers in Alzheimer's disease therapeutics‏
670 ‎‡a Author's Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced deoxyribonucleic acid damage‏
670 ‎‡a Author's Gender differences in Alzheimer disease: the role of luteinizing hormone in disease pathogenesis‏
670 ‎‡a Author's Getting the iron out: phlebotomy for Alzheimer's disease?‏
670 ‎‡a Author's Gonadotropins: a cohesive gender-based etiology of Alzheimer disease‏
670 ‎‡a Author's Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes‏
670 ‎‡a Author's Heme-a, the heme prosthetic group of cytochrome c oxidase, is increased in Alzheimer's disease‏
670 ‎‡a Author's Heme catabolism and heme oxygenase in neurodegenerative disease‏
670 ‎‡a Author's Heme deficiency in Alzheimer's disease: a possible connection to porphyria‏
670 ‎‡a Author's Hibernation, a Model of Neuroprotection‏
670 ‎‡a Author's High molecular weight neurofilament proteins are physiological substrates of adduction by the lipid peroxidation product hydroxynonenal‏
670 ‎‡a Author's Hippocampal neurogenesis and PSA-NCAM expression following exposure to 56Fe particles mimics that seen during aging in rats‏
670 ‎‡a Author's Homocysteine and Alzheimer's disease: a modifiable risk?‏
670 ‎‡a Author's Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans‏
670 ‎‡a Author's Hydroxynonenal-generated crosslinking fluorophore accumulation in Alzheimer disease reveals a dichotomy of protein turnover‏
670 ‎‡a Author's Hydroxynonenal, toxic carbonyls, and Alzheimer disease‏
670 ‎‡a Author's Ill-fated amyloid-beta vaccine‏
670 ‎‡a Author's Impaired balance of mitochondrial fission and fusion in Alzheimer's disease‏
670 ‎‡a Author's Increased expression of p130 in Alzheimer disease‏
670 ‎‡a Author's Increased expression of the remodeling- and tumorigenic-associated factor osteopontin in pyramidal neurons of the Alzheimer's disease brain‏
670 ‎‡a Author's Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment‏
670 ‎‡a Author's Increased isoprostane and prostaglandin are prominent in neurons in Alzheimer disease‏
670 ‎‡a Author's Increased p27, an essential component of cell cycle control, in Alzheimer's disease‏
670 ‎‡a Author's Increases in luteinizing hormone are associated with declines in cognitive performance‏
670 ‎‡a Author's Indices of metabolic dysfunction and oxidative stress‏
670 ‎‡a Author's Indoleamine 2,3-dioxygenase and 3-hydroxykynurenine modifications are found in the neuropathology of Alzheimer's disease‏
670 ‎‡a Author's Inhibition of Polo-like kinase 1 reduces beta-amyloid-induced neuronal cell death in Alzheimer's disease‏
670 ‎‡a Author's Insights into amyloid-beta-induced mitochondrial dysfunction in Alzheimer disease‏
670 ‎‡a Author's Insights into cerebrovascular complications and Alzheimer disease through the selective loss of GRK2 regulation‏
670 ‎‡a Author's Insulin and Insulin-Sensitizing Drugs in Neurodegeneration: Mitochondria as Therapeutic Targets‏
670 ‎‡a Author's Insulin is a two-edged knife on the brain‏
670 ‎‡a Author's Insulin-resistant brain state: the culprit in sporadic Alzheimer's disease?‏
670 ‎‡a Author's Insulin signaling, diabetes mellitus and risk of Alzheimer disease.‏
670 ‎‡a Author's Intraneuronal amyloid beta accumulation and oxidative damage to nucleic acids in Alzheimer disease‏
670 ‎‡a Author's Involvement of Maillard reactions in Alzheimer disease‏
670 ‎‡a Author's Involvement of oxidative stress in Alzheimer disease‏
670 ‎‡a Author's Iron: A Pathological Mediator of Alzheimer Disease?‏
670 ‎‡a Author's Iron homeostasis is maintained in the brain, but not the liver, following mild hypoxia‏
670 ‎‡a Author's Iron: the Redox-active center of oxidative stress in Alzheimer disease‏
670 ‎‡a Author's Iron, zinc and copper in the Alzheimer's disease brain: A quantitative meta-analysis. Some insight on the influence of citation bias on scientific opinion‏
670 ‎‡a Author's Is Alzheimer's disease a mitochondrial disorder?‏
670 ‎‡a Author's Is Alzheimers Disease a Myth? When is Disease a Disease?‏
670 ‎‡a Author's Is intraneuronal amyloid beta-peptide accumulation the trigger of Alzheimer's disease pathophysiology?‏
670 ‎‡a Author's Is nitric oxide a key target in the pathogenesis of brain lesions during the development of Alzheimer's disease?‏
670 ‎‡a Author's Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases?‏
670 ‎‡a Author's Is the time dimension of the cell cycle re-entry in AD regulated by centromere cohesion dynamics?‏
670 ‎‡a Author's JKK1, an upstream activator of JNK/SAPK, is activated in Alzheimer's disease‏
670 ‎‡a Author's Klf15 orchestrates circadian nitrogen homeostasis‏
670 ‎‡a Author's La función del estrés oxidativo en la patogénesis de la enfermedad de Alzheimer‏
670 ‎‡a Author's Labeling of cerebral amyloid beta deposits in vivo using intranasal basic fibroblast growth factor and serum amyloid P component in mice‏
670 ‎‡a Author's Leptin: a novel therapeutic strategy for Alzheimer's disease‏
670 ‎‡a Author's Leptin boosts cellular metabolism by activating AMPK and the sirtuins to reduce tau phosphorylation and β-amyloid in neurons‏
670 ‎‡a Author's Leptin inhibits glycogen synthase kinase-3beta to prevent tau phosphorylation in neuronal cells‏
670 ‎‡a Author's Leptin reduces Alzheimer's disease-related tau phosphorylation in neuronal cells‏
670 ‎‡a Author's Leptin reduces pathology and improves memory in a transgenic mouse model of Alzheimer's disease‏
670 ‎‡a Author's Leucine-rich repeat kinase 2 colocalizes with Alpha -synuclein in Parkinson's disease, but not tau-containing deposits in tauopathies‏
670 ‎‡a Author's Lipid peroxidation and 4-hydroxy-2-nonenal formation by copper ion bound to amyloid-beta peptide‏
670 ‎‡a Author's Lipoic acid and N-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts.‏
670 ‎‡a Author's Lipoic acid and N-acetyl cysteine protect against mitochondrial-related oxidative stress in fibroblasts from Alzheimer disease patients‏
670 ‎‡a Author's Low-dose pterostilbene, but not resveratrol, is a potent neuromodulator in aging and Alzheimer's disease‏
670 ‎‡a Author's LRRK2 in Parkinson's disease and dementia with Lewy bodies‏
670 ‎‡a Author's LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease‏
670 ‎‡a Author's LRRK2 protein is a component of lewy bodies‏
670 ‎‡a Author's Luteinizing hormone, a reproductive regulator that modulates the processing of amyloid-beta precursor protein and amyloid-beta deposition‏
670 ‎‡a Author's Luteinizing hormone modulates cognition and amyloid-beta deposition in Alzheimer APP transgenic mice‏
670 ‎‡a Author's Malignant glioma progression and nitric oxide‏
670 ‎‡a Author's MAPKs are differentially modulated in arctic ground squirrels during hibernation‏
670 ‎‡a Author's Mathematical modeling of microtubule dynamics: insights into physiology and disease‏
670 ‎‡a Author's Melatonin exhibits antioxidant properties in a mouse brain slice model of excitotoxicity‏
670 ‎‡a Author's Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease‏
670 ‎‡a Author's Memantine: "hypothesis testing" not "disease modifying" in Alzheimer's disease‏
670 ‎‡a Author's Menopause, estrogen, and gonadotropins in Alzheimer's disease‏
670 ‎‡a Author's Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence‏
670 ‎‡a Author's Metal chelators coupled with nanoparticles as potential therapeutic agents for Alzheimer's disease‏
670 ‎‡a Author's Metal Homeostasis and Its Relation to Oxidative Stress in Alzheimer’s Disease‏
670 ‎‡a Author's Metal ions and oxidative protein modification in neurological disease.‏
670 ‎‡a Author's Microbial origin of glutamate, hibernation and tissue trauma: an in vivo microdialysis study‏
670 ‎‡a Author's Microglial activation and amyloid-beta clearance induced by exogenous heat-shock proteins‏
670 ‎‡a Author's Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation‏
670 ‎‡a Author's Microtubule Reduction in Alzheimer's Disease and Aging Is Independent of τ Filament Formation‏
670 ‎‡a Author's Mislocalization of CDK11/PITSLRE, a regulator of the G2/M phase of the cell cycle, in Alzheimer disease‏
670 ‎‡a Author's Mitochondria: a therapeutic target in neurodegeneration‏
670 ‎‡a Author's Mitochondria and Neurodegenerative Diseases‏
670 ‎‡a Author's Mitochondria and vascular lesions as a central target for the development of Alzheimer's disease and Alzheimer disease-like pathology in transgenic mice‏
670 ‎‡a Author's Mitochondria as a primary target for vascular hypoperfusion and oxidative stress in Alzheimer's disease‏
670 ‎‡a Author's Mitochondria DNA deletions in atherosclerotic hypoperfused brain microvessels as a primary target for the development of Alzheimer's disease‏
670 ‎‡a Author's Mitochondria: the missing link between preconditioning and neuroprotection‏
670 ‎‡a Author's Mitochondrial abnormalities and oxidative imbalance in Alzheimer disease.‏
670 ‎‡a Author's Mitochondrial abnormalities and oxidative imbalance in neurodegenerative disease.‏
670 ‎‡a Author's Mitochondrial abnormalities in a streptozotocin-induced rat model of sporadic Alzheimer's disease‏
670 ‎‡a Author's Mitochondrial DNA oxidative damage and repair in aging and Alzheimer's disease‏
670 ‎‡a Author's Mitochondrial Drugs for Alzheimer Disease‏
670 ‎‡a Author's Mitochondrial dynamics in Alzheimer's disease: opportunities for future treatment strategies‏
670 ‎‡a Author's Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology‏
670 ‎‡a Author's Mitochondrial failures in Alzheimer's disease‏
670 ‎‡a Author's Mitochondrial importance in Alzheimer's, Huntington's and Parkinson's diseases‏
670 ‎‡a Author's Mitochondrial preconditioning: a potential neuroprotective strategy‏
670 ‎‡a Author's Mitogen- and stress-activated protein kinase 1: convergence of the ERK and p38 pathways in Alzheimer's disease‏
670 ‎‡a Author's Modeling cholesterol metabolism by gene expression profiling in the hippocampus‏
670 ‎‡a Author's Modeling the heterogeneity in risk of progression to Alzheimer's disease across cognitive profiles in mild cognitive impairment‏
670 ‎‡a Author's Modification of amyloid-β1-42 fibril structure by methionine-35 oxidation‏
670 ‎‡a Author's Modulation of hippocampal plasticity and cognitive behavior by short-term blueberry supplementation in aged rats‏
670 ‎‡a Author's Molecular neuropathogenesis of Alzheimer's disease: an interaction model stressing the central role of oxidative stress‏
670 ‎‡a Author's Molecular pathogenesis of Alzheimer's disease: reductionist versus expansionist approaches‏
670 ‎‡a Author's Nanoparticle and iron chelators as a potential novel Alzheimer therapy‏
670 ‎‡a Author's Nanoparticle and other metal chelation therapeutics in Alzheimer disease‏
670 ‎‡a Author's Nanoparticle-chelator conjugates as inhibitors of amyloid-beta aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease‏
670 ‎‡a Author's Nanoparticle delivery of transition-metal chelators to the brain: Oxidative stress will never see it coming!‏
670 ‎‡a Author's Nanoparticle-iron Chelator Conjugates as Multifunctional Disease-modifying Drugs for Prevention and Treatment of Alzheimer’s Disease‏
670 ‎‡a Author's Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance‏
670 ‎‡a Author's Natural Oxidant Balance in Parkinson Disease‏
670 ‎‡a Author's Neurodegenerative diseases: mechanisms and therapies‏
670 ‎‡a Author's Neurodegenerative processes in Alzheimer’s disease: an overview of pathogenesis with strategic biomarker potential‏
670 ‎‡a Author's Neuroendocrinology-based therapy for Alzheimer's disease‏
670 ‎‡a Author's Neurofibrillary Tangle Formation as a Protective Response to Oxidative Stress in Alzheimer’s Disease‏
670 ‎‡a Author's Neurofilamentopathy in neurodegenerative diseases‏
670 ‎‡a Author's Neurogenesis in Alzheimer’s Disease‏
670 ‎‡a Author's Neurogenesis in Human Hippocampus: Implications for Alzheimer Disease Pathogenesis‏
670 ‎‡a Author's Neuronal cell cycle re-entry markers are altered in the senescence accelerated mouse P8‏
670 ‎‡a Author's Neuronal cell cycle re-entry markers are altered in the senescence accelerated mouse P8 (SAMP8).‏
670 ‎‡a Author's Neuronal failure in Alzheimer's disease: a view through the oxidative stress looking-glass‏
670 ‎‡a Author's Neuronal leptin resistance in Alzheimer's disease‏
670 ‎‡a Author's Neuronal mitochondrial amelioration by feeding acetyl-L-carnitine and lipoic acid to aged rats‏
670 ‎‡a Author's Neuronal RNA oxidation is a prominent feature of dementia with Lewy bodies‏
670 ‎‡a Author's Neuronal RNA oxidation is a prominent feature of familial Alzheimer's disease‏
670 ‎‡a Author's Neuronal Survival and Death in Alzheimer Disease‏
670 ‎‡a Author's Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees?‏
670 ‎‡a Author's Neuropathology in Alzheimer's disease: awaking from a hundred-year-old dream‏
670 ‎‡a Author's Neuropathology of Alzheimer disease: pathognomonic but not pathogenic‏
670 ‎‡a Author's Neuroprotective effect of cocoa flavonoids on in vitro oxidative stress‏
670 ‎‡a Author's Neuroprotective effects of caffeine against complex I inhibition-induced apoptosis are mediated by inhibition of the Atm/p53/E2F-1 path in cerebellar granule neurons‏
670 ‎‡a Author's Neuroprotective effects of SB-415286 on hydrogen peroxide-induced cell death in B65 rat neuroblastoma cells and neurons‏
670 ‎‡a Author's Neuroprotective properties of Bcl-w in Alzheimer disease‏
670 ‎‡a Author's Neurotoxic dopamine quinone facilitates the assembly of tau into fibrillar polymers‏
670 ‎‡a Author's New insights into the mechanisms of mitochondrial preconditioning-triggered neuroprotection‏
670 ‎‡a Author's NMR studies of zinc, copper, and iron binding to histidine, the principal metal ion comple xing site of amyloid-beta peptide‏
670 ‎‡a Author's Novel therapeutics for Alzheimer's disease: an update‏
670 ‎‡a Author's Nuclear and mitochondrial DNA oxidation in Alzheimer's disease‏
670 ‎‡a Author's Nucleic acid oxidation in Alzheimer disease‏
670 ‎‡a Author's O2-04-07 Elevated expression of a regulator of the G2/M phase of the cell cycle, neuronal CIP-1 associated regulator of cyclin B, in Alzheimer disease‏
670 ‎‡a Author's Overexpression of GRK2 in Alzheimer disease and in a chronic hypoperfusion rat model is an early marker of brain mitochondrial lesions‏
670 ‎‡a Author's Oxidative damage and Alzheimer's disease: are antioxidant therapies useful?‏
670 ‎‡a Author's Oxidative Damage and Antioxidant Responses in Alzheimer's Disease‏
670 ‎‡a Author's Oxidative damage in cultured human olfactory neurons from Alzheimer's disease patients‏
670 ‎‡a Author's Oxidative damage in the olfactory system in Alzheimer's disease‏
670 ‎‡a Author's Oxidative damage is present in the fatal brain edema of diabetic ketoacidosis‏
670 ‎‡a Author's Oxidative damage to nucleic acids in human prion disease‏
670 ‎‡a Author's Oxidative damage to RNA in aging and neurodegenerative disorders‏
670 ‎‡a Author's Oxidative damage to RNA in neurodegenerative diseases‏
670 ‎‡a Author's Oxidative imbalance in Alzheimer's disease‏
670 ‎‡a Author's Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein‏
670 ‎‡a Author's Oxidative Stress and Alzheimer Disease: Mechanisms and Therapeutic Opportunities‏
670 ‎‡a Author's Oxidative Stress and Balance in Neurodegenerative Diseases‏
670 ‎‡a Author's Oxidative stress and iron imbalance in Alzheimer disease: how rust became the fuss!‏
670 ‎‡a Author's Oxidative Stress and its Implications for Future Treatments and Management of Alzheimer Disease‏
670 ‎‡a Author's Oxidative stress and neurodegeneration‏
670 ‎‡a Author's Oxidative Stress and Neurodegeneration: An Inevitable Consequence of Aging? Implications for Therapy‏
670 ‎‡a Author's Oxidative stress and neuronal adaptation in Alzheimer disease: the role of SAPK pathways‏
670 ‎‡a Author's Oxidative stress and neurotoxicity‏
670 ‎‡a Author's Oxidative stress and redox-active iron in Alzheimer's disease‏
670 ‎‡a Author's Oxidative stress in Alzheimer disease: a possibility for prevention‏
670 ‎‡a Author's Oxidative Stress in Alzheimer’s Disease: A Critical Appraisal of the Causes and the Consequences‏
670 ‎‡a Author's Oxidative stress in diabetes and Alzheimer's disease‏
670 ‎‡a Author's Oxidative Stress in Parkinson`s Disease‏
670 ‎‡a Author's Oxidative stress increases expression and activity of BACE in NT2 neurons‏
670 ‎‡a Author's Oxidative stress is an early event in hydrostatic pressure induced retinal ganglion cell damage‏
670 ‎‡a Author's Oxidative Stress Mechanisms and Potential Therapeutic Modalities in Alzheimer Disease‏
670 ‎‡a Author's Oxidative stress signalling in Alzheimer's disease‏
670 ‎‡a Author's Oxidative stress: the old enemy in Alzheimer's disease pathophysiology‏
670 ‎‡a Author's P1-266 The critical role of the ERK pathway in the pathogenesis of Alzheimer's disease‏
670 ‎‡a Author's P1-351: A novel approach to diagnosis: Antigen-antibody disassociation in Alzheimer's disease‏
670 ‎‡a Author's P3-219 Acetylation: a novel posttranslational modification in Alzheimer disease‏
670 ‎‡a Author's P3-306 Differential expression of metabotrophic glutamate receptors‏
670 ‎‡a Author's P3-306 Differential expression of metabotrophic glutamate receptors (MGlurs) in Alzheimer disease‏
670 ‎‡a Author's P3-317: Failure in the control of cell cycle causes neurodegeneration‏
670 ‎‡a Author's P3-375‏
670 ‎‡a Author's P38 activation mediates amyloid-beta cytotoxicity‏
670 ‎‡a Author's P4-162‏
670 ‎‡a Author's P4-166: Overexpression of amyloid precursor protein causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins‏
670 ‎‡a Author's Paraffin-embedded tissue‏
670 ‎‡a Author's Paraffin-embedded tissue (PET) blot method: application to Alzheimer disease‏
670 ‎‡a Author's Pathological implications of cell cycle re-entry in Alzheimer disease‏
670 ‎‡a Author's Pathology's new role: defining disease process and protective responses.‏
670 ‎‡a Author's Perspectives on the amyloid-beta cascade hypothesis‏
670 ‎‡a Author's Perspectives on the Amyloid-β Cascade Hypothesis‏
670 ‎‡a Author's Phosphorylated tau: toxic, protective, or none of the above‏
670 ‎‡a Author's Physiological regulation of tau phosphorylation during hibernation‏
670 ‎‡a Author's PKC inhibition is involved in trichosanthin-induced apoptosis in human chronic myeloid leukemia cell line K562.‏
670 ‎‡a Author's Possible involvement of Wiskott-Aldrich syndrome protein family in aberrant neuronal sprouting in Alzheimer's disease‏
670 ‎‡a Author's Predicting the failure of amyloid-beta vaccine.‏
670 ‎‡a Author's Premature centromere division of metaphase chromosomes in peripheral blood lymphocytes of Alzheimer's disease patients: relation to gender and age.‏
670 ‎‡a Author's Premature centromere division of the X chromosome in neurons in Alzheimer's disease‏
670 ‎‡a Author's Presenilin 1 overexpressions in Chinese hamster ovary‏
670 ‎‡a Author's Presenilin 1 overexpressions in Chinese hamster ovary (CHO) cells decreases the phosphorylation of retinoblastoma protein: relevance for neurodegeneration.‏
670 ‎‡a Author's Presenilin mutation: a deadly first hit in Alzheimer disease. A commentary on "aging sensitizes towards ROS formation and lipid peroxidation in PS1M146L transgenic mice".‏
670 ‎‡a Author's Prevention and treatment of Alzheimer disease and aging: antioxidants‏
670 ‎‡a Author's Prion disease and Alzheimer's disease: pathogenic overlap‏
670 ‎‡a Author's Protein Misfolding in Alzheimer's Disease‏
670 ‎‡a Author's Protein modification by dicarbonyl molecular species in neurodegenerative diseases‏
670 ‎‡a Author's Proton magnetic resonance imaging and spectroscopy identify metabolic changes in the striatum in the MPTP feline model of parkinsonism‏
670 ‎‡a Author's R-_-Lipoic Acid as a Potent Agent of Mitochondrial Protectionin Alzheimer’s Disease‏
670 ‎‡a Author's Redox Active Iron at the Center of Oxidative Stress in Alzheimer Disease‏
670 ‎‡a Author's Redox metals and oxidative abnormalities in human prion diseases‏
670 ‎‡a Author's Reduced homocysteine-thiolactonase activity in Alzheimer's disease‏
670 ‎‡a Author's Reduction of inclusion body pathology in ApoE-deficient mice fed a combination of antioxidants‏
670 ‎‡a Author's Reexamining Alzheimer's disease: evidence for a protective role for amyloid-beta protein precursor and amyloid-beta‏
670 ‎‡a Author's Regulation of glycogen synthase kinase-3beta by products of lipid peroxidation in human neuroblastoma cells‏
670 ‎‡a Author's Resveratrol and neurodegenerative diseases: activation of SIRT1 as the potential pathway towards neuroprotection‏
670 ‎‡a Author's Retinoblastoma protein phosphorylation at multiple sites is associated with neurofibrillary pathology in Alzheimer disease.‏
670 ‎‡a Author's Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron‏
670 ‎‡a Author's RNA oxidation in Alzheimer disease and related neurodegenerative disorders‏
670 ‎‡a Author's Role of high mobility group protein-1‏
670 ‎‡a Author's Role of high mobility group protein-1 (HMG1) in amyloid-beta homeostasis‏
670 ‎‡a Author's Role of metal dyshomeostasis in Alzheimer's disease‏
670 ‎‡a Author's Role of mitochondrial dysfunction in Alzheimer's disease‏
670 ‎‡a Author's Role of mitochondrial-mediated signaling pathways in Alzheimer disease and hypoxia‏
670 ‎‡a Author's Role of Oxidative Insult and Neuronal Survival in Alzheimer’s and Parkinson’s Diseases‏
670 ‎‡a Author's Role of vascular hypoperfusion-induced oxidative stress and mitochondria failure in the pathogenesis of Azheimer disease‏
670 ‎‡a Author's S4-02-01 Alzheimer disease: the two hit hypothesis‏
670 ‎‡a Author's Senile plaque composition and posttranslational modification of amyloid-beta peptide and associated proteins‏
670 ‎‡a Author's Sequestration of p27 within the cytoplasm of cardiac myocytes in chronic ischemic heart disease: pathogenic implications for ischemic cardiomyopathy‏
670 ‎‡a Author's Signal transduction cascades associated with oxidative stress in Alzheimer's disease‏
670 ‎‡a Author's Signal Transduction in Alzheimer’s Disease‏
670 ‎‡a Author's Signaling effect of amyloid-beta(42) on the processing of AbetaPP‏
670 ‎‡a Author's Soluble amyloid beta-protein is increased in frontotemporal dementia with tau gene mutations.‏
670 ‎‡a Author's Specific reaction of Met 35 in amyloid beta peptide with hypochlorous acid‏
670 ‎‡a Author's Staying connected: synapses in Alzheimer disease‏
670 ‎‡a Author's Steroidogenic acute regulatory protein (StAR): evidence of gonadotropin-induced steroidogenesis in Alzheimer disease‏
670 ‎‡a Author's Subcellular and metabolic examination of amyloid-beta peptides in Alzheimer disease pathogenesis: evidence for Abeta‏
670 ‎‡a Author's Subcellular and metabolic examination of amyloid-beta peptides in Alzheimer disease pathogenesis: evidence for Abeta(25-35).‏
670 ‎‡a Author's Sublethal RNA oxidation as a mechanism for neurodegenerative disease‏
670 ‎‡a Author's Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy‏
670 ‎‡a Author's Targeting gonadotropins: an alternative option for Alzheimer disease treatment‏
670 ‎‡a Author's Tau--an inhibitor of deacetylase HDAC6 function‏
670 ‎‡a Author's Tau modifiers as therapeutic targets for Alzheimer's disease‏
670 ‎‡a Author's Tau phosphorylation and assembly.‏
670 ‎‡a Author's Tau phosphorylation in Alzheimer's disease: pathogen or protector?‏
670 ‎‡a Author's Telomeres and telomerase in Alzheimer's disease: epiphenomena or a new focus for therapeutic strategy?‏
670 ‎‡a Author's Temporal Primacy of Oxidative Stress in the Pathological Cascade of Alzheimer Disease‏
670 ‎‡a Author's The application of microarray technology to neuropathology: cutting edge tool with clinical diagnostics potential or too much information?‏
670 ‎‡a Author's The blood-brain barrier in Alzheimer's disease: novel therapeutic targets and nanodrug delivery‏
670 ‎‡a Author's The cell cycle and hormonal fluxes in Alzheimer disease: a novel therapeutic target‏
670 ‎‡a Author's The cell cycle hypothesis of Alzheimer's disease: suggestions for drug development‏
670 ‎‡a Author's The cell cycle in Alzheimer disease: a unique target for neuropharmacology‏
670 ‎‡a Author's The cell cycle regulator phosphorylated retinoblastoma protein is associated with tau pathology in several tauopathies‏
670 ‎‡a Author's The contribution of luteinizing hormone to Alzheimer disease pathogenesis‏
670 ‎‡a Author's The "Down's" side of mitochondria‏
670 ‎‡a Author's The earliest stage of cognitive impairment in transition from normal aging to Alzheimer disease is marked by prominent RNA oxidation in vulnerable neurons‏
670 ‎‡a Author's The effect of mGluR2 activation on signal transduction pathways and neuronal cell survival‏
670 ‎‡a Author's The essential role of ERK in 4-oxo-2-nonenal-mediated cytotoxicity in SH-SY5Y human neuroblastoma cells‏
670 ‎‡a Author's The estrogen myth: potential use of gonadotropin-releasing hormone agonists for the treatment of Alzheimer's disease‏
670 ‎‡a Author's The fallacy of amyloid and cognition in Alzheimer's disease‏
670 ‎‡a Author's The gonadotropin connection in Alzheimer's disease‏
670 ‎‡a Author's The Key Role of Oxidative Stress in Alzheimer's Disease‏
670 ‎‡a Author's The mitochondrial dynamics of Alzheimer's disease and Parkinson's disease offer important opportunities for therapeutic intervention‏
670 ‎‡a Author's The neuronal expression of MYC causes a neurodegenerative phenotype in a novel transgenic mouse‏
670 ‎‡a Author's The neuroprotective activities of melatonin against the Alzheimer beta-protein are not mediated by melatonin membrane receptors‏
670 ‎‡a Author's The p38 pathway is activated in Pick disease and progressive supranuclear palsy: a mechanistic link between mitogenic pathways, oxidative stress, and tau.‏
670 ‎‡a Author's The Potential Application of Antioxidant Agents in Alzheimer Disease Therapeutics‏
670 ‎‡a Author's The role of abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease‏
670 ‎‡a Author's The role of E2F1 in the development of hypertrophic cardiomyopathy‏
670 ‎‡a Author's The role of iron and copper in the aetiology of neurodegenerative disorders: therapeutic implications‏
670 ‎‡a Author's The role of mitogen-activated protein kinase pathways in Alzheimer's disease‏
670 ‎‡a Author's The role of novel chitin-like polysaccharides in Alzheimer disease‏
670 ‎‡a Author's The role of oxidative stress in the pathophysiology of cerebrovascular lesions in Alzheimer's disease‏
670 ‎‡a Author's The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considerations‏
670 ‎‡a Author's The state versus amyloid-beta: the trial of the most wanted criminal in Alzheimer disease‏
670 ‎‡a Author's The (un)balance between metabolic and oxidative abnormalities and cellular compensatory responses in Alzheimer disease‏
670 ‎‡a Author's The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1 Alpha ‏
670 ‎‡a Author's The X-chromosome instability phenotype in Alzheimer's disease: a clinical sign of accelerating aging?‏
670 ‎‡a Author's Therapeutic opportunities in Alzheimer disease: one for all or all for one?‏
670 ‎‡a Author's Therapeutic options in Alzheimer's disease‏
670 ‎‡a Author's Therapeutic potential of c-Myc inhibition in the treatment of hypertrophic cardiomyopathy‏
670 ‎‡a Author's Therapeutic potential of oxidant mechanisms in Alzheimer's disease‏
670 ‎‡a Author's Thinking Outside the Box in Alzheimer Disease Treatment‏
670 ‎‡a Author's Three-dimensional tomographic imaging and characterization of iron compounds within Alzheimer's plaque core material‏
670 ‎‡a Author's Three histidine residues of amyloid-beta peptide control the redox activity of copper and iron‏
670 ‎‡a Author's Tipping the apoptotic balance in Alzheimer's disease: the abortosis concept‏
670 ‎‡a Author's Transgenic Mouse Models of Alzheimer's Disease‏
670 ‎‡a Author's Treating the lesions, not the disease‏
670 ‎‡a Author's Treatment advances in Alzheimer's disease based on the oxidative stress model‏
670 ‎‡a Author's Two Hits and You’re Out? A Novel Mechanistic Hypothesis of Alzheimer Disease‏
670 ‎‡a Author's Up-regulation of astrocyte metabotropic glutamate receptor 5 by amyloid-β peptide‏
670 ‎‡a Author's Vascular oxidative stress in Alzheimer disease‏
670 ‎‡a Author's Widespread distribution of reticulon-3 in various neurodegenerative diseases‏
670 ‎‡a Author's Will Preventing Protein Aggregates Live Up to Its Promise as Prophylaxis Against Neurodegenerative Diseases?‏
670 ‎‡a wikidata authority control‏ ‎‡u https://viaf.org/processed/NUKAT|n 2005130959‏
670 ‎‡a wikidata authority control‏ ‎‡u https://viaf.org/processed/ISNI|0000000019415688‏
670 ‎‡a wikidata authority control‏ ‎‡u https://viaf.org/processed/BNF|15021893‏
670 ‎‡a wikidata authority control‏ ‎‡u https://viaf.org/viaf/328144783016890843210‏
670 ‎‡a wikidata authority control‏ ‎‡u https://viaf.org/processed/LC|n 2013031838‏
670 ‎‡a wikidata site links‏ ‎‡u https://en.wikipedia.org/wiki/Mark_A._Smith‏
909 ‎‡a (orcid) 0000000237394459‏ ‎‡9 1‏
909 ‎‡a (scopus) 55574203004‏ ‎‡9 1‏
919 ‎‡a oxidativestressandneurodegeneration‏ ‎‡A Oxidative stress and neurodegeneration‏ ‎‡9 1‏
919 ‎‡a oxidativestressandneurodegenerationaninevitableconsequenceofagingimplicationsfortherapy‏ ‎‡A Oxidative Stress and Neurodegeneration: An Inevitable Consequence of Aging? Implications for Therapy‏ ‎‡9 1‏
919 ‎‡a oxidativestressandneuronaladaptationinalzheimerdiseasetheroleofsapkpathways‏ ‎‡A Oxidative stress and neuronal adaptation in Alzheimer disease: the role of SAPK pathways‏ ‎‡9 1‏
919 ‎‡a oxidativestressandneurotoxicity‏ ‎‡A Oxidative stress and neurotoxicity‏ ‎‡9 1‏
919 ‎‡a oxidativestressandredoxactiveironinalzheimersdisease‏ ‎‡A Oxidative stress and redox-active iron in Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a oxidativestressinalzheimerdiseaseapossibilityforprevention‏ ‎‡A Oxidative stress in Alzheimer disease: a possibility for prevention‏ ‎‡9 1‏
919 ‎‡a oxidativestressinalzheimersdiseaseacriticalappraisalofthecausesandtheconsequences‏ ‎‡A Oxidative Stress in Alzheimer’s Disease: A Critical Appraisal of the Causes and the Consequences‏ ‎‡9 1‏
919 ‎‡a oxidativestressindiabetesandalzheimersdisease‏ ‎‡A Oxidative stress in diabetes and Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a oxidativestressinparkinsonsdisease‏ ‎‡A Oxidative Stress in Parkinson`s Disease‏ ‎‡9 1‏
919 ‎‡a oxidativestressincreasesexpressionandactivityofbaceinnt2neurons‏ ‎‡A Oxidative stress increases expression and activity of BACE in NT2 neurons‏ ‎‡9 1‏
919 ‎‡a oxidativestressisanearlyeventinhydrostaticpressureinducedretinalganglioncelldamage‏ ‎‡A Oxidative stress is an early event in hydrostatic pressure induced retinal ganglion cell damage‏ ‎‡9 1‏
919 ‎‡a oxidativestressmechanismsandpotentialtherapeuticmodalitiesinalzheimerdisease‏ ‎‡A Oxidative Stress Mechanisms and Potential Therapeutic Modalities in Alzheimer Disease‏ ‎‡9 1‏
919 ‎‡a oxidativestresssignallinginalzheimersdisease‏ ‎‡A Oxidative stress signalling in Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a oxidativestresstheoldenemyinalzheimersdiseasepathophysiology‏ ‎‡A Oxidative stress: the old enemy in Alzheimer's disease pathophysiology‏ ‎‡9 1‏
919 ‎‡a p1266thecriticalroleoftheerkpathwayinthepathogenesisofalzheimersdisease‏ ‎‡A P1-266 The critical role of the ERK pathway in the pathogenesis of Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a p1351anovelapproachtodiagnosisantigenantibodydisassociationinalzheimersdisease‏ ‎‡A P1-351: A novel approach to diagnosis: Antigen-antibody disassociation in Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a p3219acetylationanovelposttranslationalmodificationinalzheimerdisease‏ ‎‡A P3-219 Acetylation: a novel posttranslational modification in Alzheimer disease‏ ‎‡9 1‏
919 ‎‡a p3306differentialexpressionofmetabotrophicglutamatereceptors‏ ‎‡A P3-306 Differential expression of metabotrophic glutamate receptors‏ ‎‡9 1‏
919 ‎‡a p3306differentialexpressionofmetabotrophicglutamatereceptorsmglursinalzheimerdisease‏ ‎‡A P3-306 Differential expression of metabotrophic glutamate receptors (MGlurs) in Alzheimer disease‏ ‎‡9 1‏
919 ‎‡a p3317failureinthecontrolofcellcyclecausesneurodegeneration‏ ‎‡A P3-317: Failure in the control of cell cycle causes neurodegeneration‏ ‎‡9 1‏
919 ‎‡a p3375‏ ‎‡A P3-375‏ ‎‡9 1‏
919 ‎‡a p38activationmediatesamyloidbetacytotoxicity‏ ‎‡A P38 activation mediates amyloid-beta cytotoxicity‏ ‎‡9 1‏
919 ‎‡a p4162‏ ‎‡A P4-162‏ ‎‡9 1‏
919 ‎‡a p4166overexpressionofamyloidprecursorproteincausesabnormalmitochondrialdynamicsviadifferentialmodulationofmitochondrialfissionfusionproteins‏ ‎‡A P4-166: Overexpression of amyloid precursor protein causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins‏ ‎‡9 1‏
919 ‎‡a paraffinembeddedtissue‏ ‎‡A Paraffin-embedded tissue‏ ‎‡9 1‏
919 ‎‡a paraffinembeddedtissuepetblotmethodapplicationtoalzheimerdisease‏ ‎‡A Paraffin-embedded tissue (PET) blot method: application to Alzheimer disease‏ ‎‡9 1‏
919 ‎‡a pathologicalimplicationsofcellcyclereentryinalzheimerdisease‏ ‎‡A Pathological implications of cell cycle re-entry in Alzheimer disease‏ ‎‡9 1‏
919 ‎‡a pathologysnewroledefiningdiseaseprocessandprotectiveresponses‏ ‎‡A Pathology's new role: defining disease process and protective responses.‏ ‎‡9 1‏
919 ‎‡a perspectivesontheamyloidbetacascadehypothesis‏ ‎‡A Perspectives on the amyloid-beta cascade hypothesis‏ ‎‡9 1‏
919 ‎‡a perspectivesontheamyloidβcascadehypothesis‏ ‎‡A Perspectives on the Amyloid-β Cascade Hypothesis‏ ‎‡9 1‏
919 ‎‡a phosphorylatedtautoxicprotectiveornoneoftheabove‏ ‎‡A Phosphorylated tau: toxic, protective, or none of the above‏ ‎‡9 1‏
919 ‎‡a physiologicalregulationoftauphosphorylationduringhibernation‏ ‎‡A Physiological regulation of tau phosphorylation during hibernation‏ ‎‡9 1‏
919 ‎‡a pkcinhibitionisinvolvedintrichosanthininducedapoptosisinhumanchronicmyeloidleukemiacelllinek562‏ ‎‡A PKC inhibition is involved in trichosanthin-induced apoptosis in human chronic myeloid leukemia cell line K562.‏ ‎‡9 1‏
919 ‎‡a possibleinvolvementofwiskottaldrichsyndromeproteinfamilyinaberrantneuronalsproutinginalzheimersdisease‏ ‎‡A Possible involvement of Wiskott-Aldrich syndrome protein family in aberrant neuronal sprouting in Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a predictingthefailureofamyloidbetavaccine‏ ‎‡A Predicting the failure of amyloid-beta vaccine.‏ ‎‡9 1‏
919 ‎‡a prematurecentromeredivisionofmetaphasechromosomesinperipheralbloodlymphocytesofalzheimersdiseasepatientsrelationtogenderandage‏ ‎‡A Premature centromere division of metaphase chromosomes in peripheral blood lymphocytes of Alzheimer's disease patients: relation to gender and age.‏ ‎‡9 1‏
919 ‎‡a prematurecentromeredivisionofthe10chromosomeinneuronsinalzheimersdisease‏ ‎‡A Premature centromere division of the X chromosome in neurons in Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a presenilin1overexpressionsinchinesehamsterovary‏ ‎‡A Presenilin 1 overexpressions in Chinese hamster ovary‏ ‎‡9 1‏
919 ‎‡a presenilin1overexpressionsinchinesehamsterovarychocellsdecreasesthephosphorylationofretinoblastomaproteinrelevanceforneurodegeneration‏ ‎‡A Presenilin 1 overexpressions in Chinese hamster ovary (CHO) cells decreases the phosphorylation of retinoblastoma protein: relevance for neurodegeneration.‏ ‎‡9 1‏
919 ‎‡a presenilinmutationadeadly1hitinalzheimerdiseaseacommentaryonagingsensitizestowardsrosformationandlipidperoxidationinps1m146ltransgenicmice‏ ‎‡A Presenilin mutation: a deadly first hit in Alzheimer disease. A commentary on "aging sensitizes towards ROS formation and lipid peroxidation in PS1M146L transgenic mice".‏ ‎‡9 1‏
919 ‎‡a preventionandtreatmentofalzheimerdiseaseandagingantioxidants‏ ‎‡A Prevention and treatment of Alzheimer disease and aging: antioxidants‏ ‎‡9 1‏
919 ‎‡a priondiseaseandalzheimersdiseasepathogenicoverlap‏ ‎‡A Prion disease and Alzheimer's disease: pathogenic overlap‏ ‎‡9 1‏
919 ‎‡a proteinmisfoldinginalzheimersdisease‏ ‎‡A Protein Misfolding in Alzheimer's Disease‏ ‎‡9 1‏
919 ‎‡a proteinmodificationbydicarbonylmolecularspeciesinneurodegenerativediseases‏ ‎‡A Protein modification by dicarbonyl molecular species in neurodegenerative diseases‏ ‎‡9 1‏
919 ‎‡a protonmagneticresonanceimagingandspectroscopyidentifymetabolicchangesinthestriatuminthemptpfelinemodelofparkinsonism‏ ‎‡A Proton magnetic resonance imaging and spectroscopy identify metabolic changes in the striatum in the MPTP feline model of parkinsonism‏ ‎‡9 1‏
919 ‎‡a rlipoicacidasapotentagentofmitochondrialprotectioninalzheimersdisease‏ ‎‡A R-_-Lipoic Acid as a Potent Agent of Mitochondrial Protectionin Alzheimer’s Disease‏ ‎‡9 1‏
919 ‎‡a redoxactiveironatthecenterofoxidativestressinalzheimerdisease‏ ‎‡A Redox Active Iron at the Center of Oxidative Stress in Alzheimer Disease‏ ‎‡9 1‏
919 ‎‡a redoxmetalsandoxidativeabnormalitiesinhumanpriondiseases‏ ‎‡A Redox metals and oxidative abnormalities in human prion diseases‏ ‎‡9 1‏
919 ‎‡a reducedhomocysteinethiolactonaseactivityinalzheimersdisease‏ ‎‡A Reduced homocysteine-thiolactonase activity in Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a reductionofinclusionbodypathologyinapoedeficientmicefedacombinationofantioxidants‏ ‎‡A Reduction of inclusion body pathology in ApoE-deficient mice fed a combination of antioxidants‏ ‎‡9 1‏
919 ‎‡a reexaminingalzheimersdiseaseevidenceforaprotectiveroleforamyloidbetaproteinprecursorandamyloidbeta‏ ‎‡A Reexamining Alzheimer's disease: evidence for a protective role for amyloid-beta protein precursor and amyloid-beta‏ ‎‡9 1‏
919 ‎‡a regulationofglycogensynthasekinase3betabyproductsoflipidperoxidationinhumanneuroblastomacells‏ ‎‡A Regulation of glycogen synthase kinase-3beta by products of lipid peroxidation in human neuroblastoma cells‏ ‎‡9 1‏
919 ‎‡a resveratrolandneurodegenerativediseasesactivationofsirt1asthepotentialpathwaytowardsneuroprotection‏ ‎‡A Resveratrol and neurodegenerative diseases: activation of SIRT1 as the potential pathway towards neuroprotection‏ ‎‡9 1‏
919 ‎‡a retinoblastomaproteinphosphorylationatmultiplesitesisassociatedwithneurofibrillarypathologyinalzheimerdisease‏ ‎‡A Retinoblastoma protein phosphorylation at multiple sites is associated with neurofibrillary pathology in Alzheimer disease.‏ ‎‡9 1‏
919 ‎‡a ribosomalrnainalzheimerdiseaseisoxidizedbyboundredoxactiveiron‏ ‎‡A Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron‏ ‎‡9 1‏
919 ‎‡a rnaoxidationinalzheimerdiseaseandrelatedneurodegenerativedisorders‏ ‎‡A RNA oxidation in Alzheimer disease and related neurodegenerative disorders‏ ‎‡9 1‏
919 ‎‡a roleofhighmobilitygroupprotein1‏ ‎‡A Role of high mobility group protein-1‏ ‎‡9 1‏
919 ‎‡a roleofhighmobilitygroupprotein1hmg1inamyloidbetahomeostasis‏ ‎‡A Role of high mobility group protein-1 (HMG1) in amyloid-beta homeostasis‏ ‎‡9 1‏
919 ‎‡a roleofmetaldyshomeostasisinalzheimersdisease‏ ‎‡A Role of metal dyshomeostasis in Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a roleofmitochondrialdysfunctioninalzheimersdisease‏ ‎‡A Role of mitochondrial dysfunction in Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a roleofmitochondrialmediatedsignalingpathwaysinalzheimerdiseaseandhypoxia‏ ‎‡A Role of mitochondrial-mediated signaling pathways in Alzheimer disease and hypoxia‏ ‎‡9 1‏
919 ‎‡a roleofoxidativeinsultandneuronalsurvivalinalzheimersandparkinsonsdiseases‏ ‎‡A Role of Oxidative Insult and Neuronal Survival in Alzheimer’s and Parkinson’s Diseases‏ ‎‡9 1‏
919 ‎‡a roleofvascularhypoperfusioninducedoxidativestressandmitochondriafailureinthepathogenesisofazheimerdisease‏ ‎‡A Role of vascular hypoperfusion-induced oxidative stress and mitochondria failure in the pathogenesis of Azheimer disease‏ ‎‡9 1‏
919 ‎‡a s40201alzheimerdiseasethe2hithypothesis‏ ‎‡A S4-02-01 Alzheimer disease: the two hit hypothesis‏ ‎‡9 1‏
919 ‎‡a senileplaquecompositionandposttranslationalmodificationofamyloidbetapeptideandassociatedproteins‏ ‎‡A Senile plaque composition and posttranslational modification of amyloid-beta peptide and associated proteins‏ ‎‡9 1‏
919 ‎‡a sequestrationofp27withinthecytoplasmofcardiacmyocytesinchronicischemicheartdiseasepathogenicimplicationsforischemiccardiomyopathy‏ ‎‡A Sequestration of p27 within the cytoplasm of cardiac myocytes in chronic ischemic heart disease: pathogenic implications for ischemic cardiomyopathy‏ ‎‡9 1‏
919 ‎‡a signaltransductioncascadesassociatedwithoxidativestressinalzheimersdisease‏ ‎‡A Signal transduction cascades associated with oxidative stress in Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a signaltransductioninalzheimersdisease‏ ‎‡A Signal Transduction in Alzheimer’s Disease‏ ‎‡9 1‏
919 ‎‡a signalingeffectofamyloidbeta42ontheprocessingofabetapp‏ ‎‡A Signaling effect of amyloid-beta(42) on the processing of AbetaPP‏ ‎‡9 1‏
919 ‎‡a solubleamyloidbetaproteinisincreasedinfrontotemporaldementiawithtaugenemutations‏ ‎‡A Soluble amyloid beta-protein is increased in frontotemporal dementia with tau gene mutations.‏ ‎‡9 1‏
919 ‎‡a specificreactionofmet35inamyloidbetapeptidewithhypochlorousacid‏ ‎‡A Specific reaction of Met 35 in amyloid beta peptide with hypochlorous acid‏ ‎‡9 1‏
919 ‎‡a stayingconnectedsynapsesinalzheimerdisease‏ ‎‡A Staying connected: synapses in Alzheimer disease‏ ‎‡9 1‏
919 ‎‡a steroidogenicacuteregulatoryproteinstarevidenceofgonadotropininducedsteroidogenesisinalzheimerdisease‏ ‎‡A Steroidogenic acute regulatory protein (StAR): evidence of gonadotropin-induced steroidogenesis in Alzheimer disease‏ ‎‡9 1‏
919 ‎‡a subcellularandmetabolicexaminationofamyloidbetapeptidesinalzheimerdiseasepathogenesisevidenceforabeta‏ ‎‡A Subcellular and metabolic examination of amyloid-beta peptides in Alzheimer disease pathogenesis: evidence for Abeta‏ ‎‡9 1‏
919 ‎‡a subcellularandmetabolicexaminationofamyloidbetapeptidesinalzheimerdiseasepathogenesisevidenceforabeta2535‏ ‎‡A Subcellular and metabolic examination of amyloid-beta peptides in Alzheimer disease pathogenesis: evidence for Abeta(25-35).‏ ‎‡9 1‏
919 ‎‡a sublethalrnaoxidationasamechanismforneurodegenerativedisease‏ ‎‡A Sublethal RNA oxidation as a mechanism for neurodegenerative disease‏ ‎‡9 1‏
919 ‎‡a systemicincreaseofoxidativenucleicaciddamageinparkinsonsdiseaseandmultiplesystematrophy‏ ‎‡A Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy‏ ‎‡9 1‏
919 ‎‡a targetinggonadotropinsanalternativeoptionforalzheimerdiseasetreatment‏ ‎‡A Targeting gonadotropins: an alternative option for Alzheimer disease treatment‏ ‎‡9 1‏
919 ‎‡a tauaninhibitorofdeacetylasehdac6function‏ ‎‡A Tau--an inhibitor of deacetylase HDAC6 function‏ ‎‡9 1‏
919 ‎‡a taumodifiersastherapeutictargetsforalzheimersdisease‏ ‎‡A Tau modifiers as therapeutic targets for Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a tauphosphorylationandassembly‏ ‎‡A Tau phosphorylation and assembly.‏ ‎‡9 1‏
919 ‎‡a tauphosphorylationinalzheimersdiseasepathogenorprotector‏ ‎‡A Tau phosphorylation in Alzheimer's disease: pathogen or protector?‏ ‎‡9 1‏
919 ‎‡a telomeresandtelomeraseinalzheimersdiseaseepiphenomenaoranewfocusfortherapeuticstrategy‏ ‎‡A Telomeres and telomerase in Alzheimer's disease: epiphenomena or a new focus for therapeutic strategy?‏ ‎‡9 1‏
919 ‎‡a temporalprimacyofoxidativestressinthepathologicalcascadeofalzheimerdisease‏ ‎‡A Temporal Primacy of Oxidative Stress in the Pathological Cascade of Alzheimer Disease‏ ‎‡9 1‏
919 ‎‡a applicationofmicroarraytechnologytoneuropathologycuttingedgetoolwithclinicaldiagnosticspotentialortoomuchinformation‏ ‎‡A The application of microarray technology to neuropathology: cutting edge tool with clinical diagnostics potential or too much information?‏ ‎‡9 1‏
919 ‎‡a bloodbrainbarrierinalzheimersdiseasenoveltherapeutictargetsandnanodrugdelivery‏ ‎‡A The blood-brain barrier in Alzheimer's disease: novel therapeutic targets and nanodrug delivery‏ ‎‡9 1‏
919 ‎‡a cellcycleandhormonalfluxesinalzheimerdiseaseanoveltherapeutictarget‏ ‎‡A The cell cycle and hormonal fluxes in Alzheimer disease: a novel therapeutic target‏ ‎‡9 1‏
919 ‎‡a cellcyclehypothesisofalzheimersdiseasesuggestionsfordrugdevelopment‏ ‎‡A The cell cycle hypothesis of Alzheimer's disease: suggestions for drug development‏ ‎‡9 1‏
919 ‎‡a cellcycleinalzheimerdiseaseauniquetargetforneuropharmacology‏ ‎‡A The cell cycle in Alzheimer disease: a unique target for neuropharmacology‏ ‎‡9 1‏
919 ‎‡a cellcycleregulatorphosphorylatedretinoblastomaproteinisassociatedwithtaupathologyinseveraltauopathies‏ ‎‡A The cell cycle regulator phosphorylated retinoblastoma protein is associated with tau pathology in several tauopathies‏ ‎‡9 1‏
919 ‎‡a contributionofluteinizinghormonetoalzheimerdiseasepathogenesis‏ ‎‡A The contribution of luteinizing hormone to Alzheimer disease pathogenesis‏ ‎‡9 1‏
919 ‎‡a downssideofmitochondria‏ ‎‡A The "Down's" side of mitochondria‏ ‎‡9 1‏
919 ‎‡a earlieststageofcognitiveimpairmentintransitionfromnormalagingtoalzheimerdiseaseismarkedbyprominentrnaoxidationinvulnerableneurons‏ ‎‡A The earliest stage of cognitive impairment in transition from normal aging to Alzheimer disease is marked by prominent RNA oxidation in vulnerable neurons‏ ‎‡9 1‏
919 ‎‡a effectofmglur2activationonsignaltransductionpathwaysandneuronalcellsurvival‏ ‎‡A The effect of mGluR2 activation on signal transduction pathways and neuronal cell survival‏ ‎‡9 1‏
919 ‎‡a essentialroleoferkin4oxo2nonenalmediatedcytotoxicityinshsy5yhumanneuroblastomacells‏ ‎‡A The essential role of ERK in 4-oxo-2-nonenal-mediated cytotoxicity in SH-SY5Y human neuroblastoma cells‏ ‎‡9 1‏
919 ‎‡a estrogenmythpotentialuseofgonadotropinreleasinghormoneagonistsforthetreatmentofalzheimersdisease‏ ‎‡A The estrogen myth: potential use of gonadotropin-releasing hormone agonists for the treatment of Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a fallacyofamyloidandcognitioninalzheimersdisease‏ ‎‡A The fallacy of amyloid and cognition in Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a gonadotropinconnectioninalzheimersdisease‏ ‎‡A The gonadotropin connection in Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a keyroleofoxidativestressinalzheimersdisease‏ ‎‡A The Key Role of Oxidative Stress in Alzheimer's Disease‏ ‎‡9 1‏
919 ‎‡a mitochondrialdynamicsofalzheimersdiseaseandparkinsonsdiseaseofferimportantopportunitiesfortherapeuticintervention‏ ‎‡A The mitochondrial dynamics of Alzheimer's disease and Parkinson's disease offer important opportunities for therapeutic intervention‏ ‎‡9 1‏
919 ‎‡a neuronalexpressionofmyccausesaneurodegenerativephenotypeinanoveltransgenicmouse‏ ‎‡A The neuronal expression of MYC causes a neurodegenerative phenotype in a novel transgenic mouse‏ ‎‡9 1‏
919 ‎‡a neuroprotectiveactivitiesofmelatoninagainstthealzheimerbetaproteinarenotmediatedbymelatoninmembranereceptors‏ ‎‡A The neuroprotective activities of melatonin against the Alzheimer beta-protein are not mediated by melatonin membrane receptors‏ ‎‡9 1‏
919 ‎‡a p38pathwayisactivatedinpickdiseaseandprogressivesupranuclearpalsyamechanisticlinkbetweenmitogenicpathwaysoxidativestressandtau‏ ‎‡A The p38 pathway is activated in Pick disease and progressive supranuclear palsy: a mechanistic link between mitogenic pathways, oxidative stress, and tau.‏ ‎‡9 1‏
919 ‎‡a potentialapplicationofantioxidantagentsinalzheimerdiseasetherapeutics‏ ‎‡A The Potential Application of Antioxidant Agents in Alzheimer Disease Therapeutics‏ ‎‡9 1‏
919 ‎‡a roleofabnormalmitochondrialdynamicsinthepathogenesisofalzheimersdisease‏ ‎‡A The role of abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a roleofe2f1inthedevelopmentofhypertrophiccardiomyopathy‏ ‎‡A The role of E2F1 in the development of hypertrophic cardiomyopathy‏ ‎‡9 1‏
919 ‎‡a roleofironandcopperintheaetiologyofneurodegenerativedisorderstherapeuticimplications‏ ‎‡A The role of iron and copper in the aetiology of neurodegenerative disorders: therapeutic implications‏ ‎‡9 1‏
919 ‎‡a roleofmitogenactivatedproteinkinasepathwaysinalzheimersdisease‏ ‎‡A The role of mitogen-activated protein kinase pathways in Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a roleofnovelchitinlikepolysaccharidesinalzheimerdisease‏ ‎‡A The role of novel chitin-like polysaccharides in Alzheimer disease‏ ‎‡9 1‏
919 ‎‡a roleofoxidativestressinthepathophysiologyofcerebrovascularlesionsinalzheimersdisease‏ ‎‡A The role of oxidative stress in the pathophysiology of cerebrovascular lesions in Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a sirtuinpathwayinageingandalzheimerdiseasemechanisticandtherapeuticconsiderations‏ ‎‡A The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considerations‏ ‎‡9 1‏
919 ‎‡a stateversusamyloidbetathetrialofthemostwantedcriminalinalzheimerdisease‏ ‎‡A The state versus amyloid-beta: the trial of the most wanted criminal in Alzheimer disease‏ ‎‡9 1‏
919 ‎‡a 1balancebetweenmetabolicandoxidativeabnormalitiesandcellularcompensatoryresponsesinalzheimerdisease‏ ‎‡A The (un)balance between metabolic and oxidative abnormalities and cellular compensatory responses in Alzheimer disease‏ ‎‡9 1‏
919 ‎‡a upregulationofbace1mediatedbyhypoxiaandischemicinjuryroleofoxidativestressandhif1 Alpha ‏ ‎‡A The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1 Alpha ‏ ‎‡9 1‏
919 ‎‡a 10chromosomeinstabilityphenotypeinalzheimersdiseaseaclinicalsignofacceleratingaging‏ ‎‡A The X-chromosome instability phenotype in Alzheimer's disease: a clinical sign of accelerating aging?‏ ‎‡9 1‏
919 ‎‡a therapeuticopportunitiesinalzheimerdisease1forallorallfor1‏ ‎‡A Therapeutic opportunities in Alzheimer disease: one for all or all for one?‏ ‎‡9 1‏
919 ‎‡a therapeuticoptionsinalzheimersdisease‏ ‎‡A Therapeutic options in Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a therapeuticpotentialof100mycinhibitioninthetreatmentofhypertrophiccardiomyopathy‏ ‎‡A Therapeutic potential of c-Myc inhibition in the treatment of hypertrophic cardiomyopathy‏ ‎‡9 1‏
919 ‎‡a therapeuticpotentialofoxidantmechanismsinalzheimersdisease‏ ‎‡A Therapeutic potential of oxidant mechanisms in Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a thinkingoutsidetheboxinalzheimerdiseasetreatment‏ ‎‡A Thinking Outside the Box in Alzheimer Disease Treatment‏ ‎‡9 1‏
919 ‎‡a 3dimensionaltomographicimagingandcharacterizationofironcompoundswithinalzheimersplaquecorematerial‏ ‎‡A Three-dimensional tomographic imaging and characterization of iron compounds within Alzheimer's plaque core material‏ ‎‡9 1‏
919 ‎‡a 3histidineresiduesofamyloidbetapeptidecontroltheredoxactivityofcopperandiron‏ ‎‡A Three histidine residues of amyloid-beta peptide control the redox activity of copper and iron‏ ‎‡9 1‏
919 ‎‡a tippingtheapoptoticbalanceinalzheimersdiseasetheabortosisconcept‏ ‎‡A Tipping the apoptotic balance in Alzheimer's disease: the abortosis concept‏ ‎‡9 1‏
919 ‎‡a transgenicmousemodelsofalzheimersdisease‏ ‎‡A Transgenic Mouse Models of Alzheimer's Disease‏ ‎‡9 1‏
919 ‎‡a treatingthelesionsnotthedisease‏ ‎‡A Treating the lesions, not the disease‏ ‎‡9 1‏
919 ‎‡a treatmentadvancesinalzheimersdiseasebasedontheoxidativestressmodel‏ ‎‡A Treatment advances in Alzheimer's disease based on the oxidative stress model‏ ‎‡9 1‏
919 ‎‡a 2hitsandyoureoutanovelmechanistichypothesisofalzheimerdisease‏ ‎‡A Two Hits and You’re Out? A Novel Mechanistic Hypothesis of Alzheimer Disease‏ ‎‡9 1‏
919 ‎‡a upregulationofastrocytemetabotropicglutamatereceptor5byamyloidβpeptide‏ ‎‡A Up-regulation of astrocyte metabotropic glutamate receptor 5 by amyloid-β peptide‏ ‎‡9 1‏
919 ‎‡a vascularoxidativestressinalzheimerdisease‏ ‎‡A Vascular oxidative stress in Alzheimer disease‏ ‎‡9 1‏
919 ‎‡a widespreaddistributionofreticulon3invariousneurodegenerativediseases‏ ‎‡A Widespread distribution of reticulon-3 in various neurodegenerative diseases‏ ‎‡9 1‏
919 ‎‡a willpreventingproteinaggregatesliveuptoitspromiseasprophylaxisagainstneurodegenerativediseases‏ ‎‡A Will Preventing Protein Aggregates Live Up to Its Promise as Prophylaxis Against Neurodegenerative Diseases?‏ ‎‡9 1‏
919 ‎‡a 4oxo2nonenalisbothmoreneurotoxicandmoreproteinreactivethan4hydroxy2nonenal‏ ‎‡A 4-Oxo-2-nonenal is both more neurotoxic and more protein reactive than 4-hydroxy-2-nonenal‏ ‎‡9 1‏
919 ‎‡a clinicalstudyofluprondepotinthetreatmentofwomenwithalzheimersdiseasepreservationofcognitivefunctioninpatientstakinganacetylcholinesteraseinhibitorandtreatedwithhighdoselupronover48weeks‏ ‎‡A A clinical study of lupron depot in the treatment of women with Alzheimer's disease: preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose lupron over 48 weeks‏ ‎‡9 1‏
919 ‎‡a metabolicbasisforalzheimerdisease‏ ‎‡A A metabolic basis for Alzheimer disease‏ ‎‡9 1‏
919 ‎‡a newmodelofoxidativestressinratpups‏ ‎‡A A new model of oxidative stress in rat pups‏ ‎‡9 1‏
919 ‎‡a novelapproachtotheidentificationandquantitativeelementalanalysisofamyloiddepositsinsightsintothepathologyofalzheimersdisease‏ ‎‡A A novel approach to the identification and quantitative elemental analysis of amyloid deposits--insights into the pathology of Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a novelendogenousindoleprotectsrodentmitochondriaandextendsrotiferlifespan‏ ‎‡A A novel endogenous indole protects rodent mitochondria and extends rotifer lifespan‏ ‎‡9 1‏
919 ‎‡a noveloriginforgranulovacuolardegenerationinagingandalzheimersdiseaseparallelstostressgranules‏ ‎‡A A novel origin for granulovacuolar degeneration in aging and Alzheimer's disease: parallels to stress granules‏ ‎‡9 1‏
919 ‎‡a 2lookintotheoxidantmechanismsinalzheimersdisease‏ ‎‡A A second look into the oxidant mechanisms in Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a synergisticdysfunctionofmitochondrialfissionfusiondynamicsandmitophagyinalzheimersdisease‏ ‎‡A A synergistic dysfunction of mitochondrial fission/fusion dynamics and mitophagy in Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a aberrantexpressionofmetabotropicglutamatereceptor2inthevulnerableneuronsofalzheimersdisease‏ ‎‡A Aberrant expression of metabotropic glutamate receptor 2 in the vulnerable neurons of Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a aberrantlocalizationofimportin Alpha 1inhippocampalneuronsinalzheimerdisease‏ ‎‡A Aberrant localization of importin Alpha 1 in hippocampal neurons in Alzheimer disease‏ ‎‡9 1‏
919 ‎‡a abnormalironmetabolismandoxidativestressinmiceexpressingamutantformoftheferritinlightpolypeptidegene‏ ‎‡A Abnormal iron metabolism and oxidative stress in mice expressing a mutant form of the ferritin light polypeptide gene‏ ‎‡9 1‏
919 ‎‡a abnormalmitochondrialdynamicsanoveltherapeutictargetforalzheimersdisease‏ ‎‡A Abnormal mitochondrial dynamics--a novel therapeutic target for Alzheimer's disease?‏ ‎‡9 1‏
919 ‎‡a abnormalmitochondrialdynamicsandneurodegenerativediseases‏ ‎‡A Abnormal mitochondrial dynamics and neurodegenerative diseases‏ ‎‡9 1‏
919 ‎‡a abnormalmitochondrialdynamicsinthepathogenesisofalzheimersdisease‏ ‎‡A Abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a absenceofcellularstressinbrainafterhypoxiainducedbyarousalfromhibernationinarcticgroundsquirrels‏ ‎‡A Absence of cellular stress in brain after hypoxia induced by arousal from hibernation in Arctic ground squirrels‏ ‎‡9 1‏
919 ‎‡a accelerated Alpha synucleinaggregationafterdifferentiationofshsy5yneuroblastomacells‏ ‎‡A Accelerated Alpha -synuclein aggregation after differentiation of SH-SY5Y neuroblastoma cells‏ ‎‡9 1‏
919 ‎‡a accumulationofintraneuronalamyloidβiscommoninnormalbrain‏ ‎‡A Accumulation of intraneuronal amyloid-β is common in normal brain.‏ ‎‡9 1‏
919 ‎‡a activationofaktbylithiumprosurvivalpathwaysinaging‏ ‎‡A Activation of Akt by lithium: pro-survival pathways in aging‏ ‎‡9 1‏
919 ‎‡a activationofp38kinaselinksπphosphorylationoxidativestressandcellcyclerelatedeventsinalzheimerdisease‏ ‎‡A Activation of P38 kinase links π phosphorylation, oxidative stress and cell cycle-related events in Alzheimer disease‏ ‎‡9 1‏
919 ‎‡a activationoftheextracellularsignalregulatedkinasepathwaycontributestothebehavioraldeficitoffragile10syndrome‏ ‎‡A Activation of the extracellular signal-regulated kinase pathway contributes to the behavioral deficit of fragile x-syndrome‏ ‎‡9 1‏
919 ‎‡a adventiouslyboundredoxactiveironandcopperareatthecenterofoxidativedamageinalzheimerdisease‏ ‎‡A Adventiously-bound redox active iron and copper are at the center of oxidative damage in Alzheimer disease‏ ‎‡9 1‏
919 ‎‡a agesragecomplexupregulatesbace1vianfκbpathwayactivation‏ ‎‡A AGEs/RAGE complex upregulates BACE1 via NF-κB pathway activation‏ ‎‡9 1‏
919 ‎‡a alltransretinoicacidasanoveltherapeuticstrategyforalzheimersdisease‏ ‎‡A All-trans retinoic acid as a novel therapeutic strategy for Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a alteredredoxbalanceindiseasecanwechangethenewequilibria‏ ‎‡A Altered redox balance in disease: Can we change the new equilibria?‏ ‎‡9 1‏
919 ‎‡a alzheimerdiseaseandtheroleoffreeradicalsinthepathogenesisofthedisease‏ ‎‡A Alzheimer disease and the role of free radicals in the pathogenesis of the disease‏ ‎‡9 1‏
919 ‎‡a alzheimerdiseaseevidenceforacentralpathogenicroleofironmediatedreactiveoxygenspecies‏ ‎‡A Alzheimer disease: evidence for a central pathogenic role of iron-mediated reactive oxygen species‏ ‎‡9 1‏
919 ‎‡a alzheimerdiseaseoxidativestressandcompensatoryresponses‏ ‎‡A Alzheimer Disease: Oxidative Stress and Compensatory Responses‏ ‎‡9 1‏
919 ‎‡a alzheimerdiseasepathologyasahostresponse‏ ‎‡A Alzheimer disease pathology as a host response‏ ‎‡9 1‏
919 ‎‡a alzheimerdiseasethe2hithypothesisanupdate‏ ‎‡A Alzheimer disease, the two-hit hypothesis: an update‏ ‎‡9 1‏
919 ‎‡a alzheimerspecificepitopesoftaurepresentlipidperoxidationinducedconformations‏ ‎‡A Alzheimer-specific epitopes of tau represent lipid peroxidation-induced conformations‏ ‎‡9 1‏
919 ‎‡a alzheimersdiseaseadvancesforanewcentury‏ ‎‡A Alzheimer's Disease: Advances for a New Century‏ ‎‡9 1‏
919 ‎‡a alzheimersdiseaseanintracellularmovementdisorder‏ ‎‡A Alzheimer's disease: an intracellular movement disorder?‏ ‎‡9 1‏
919 ‎‡a alzheimersdiseaseandoxidativestresstheoldproblemremainsunsolved‏ ‎‡A Alzheimers Disease and Oxidative Stress: The Old Problem Remains Unsolved‏ ‎‡9 1‏
919 ‎‡a alzheimersdiseaseandthecellcycle‏ ‎‡A Alzheimer's disease and the cell cycle‏ ‎‡9 1‏
919 ‎‡a alzheimersdiseasecerebrovasculardysfunctionoxidativestressandadvancedclinicaltherapies‏ ‎‡A Alzheimer's disease: cerebrovascular dysfunction, oxidative stress, and advanced clinical therapies‏ ‎‡9 1‏
919 ‎‡a alzheimersdiseasediverseaspectsofmitochondrialmalfunctioning‏ ‎‡A Alzheimer's disease: diverse aspects of mitochondrial malfunctioning‏ ‎‡9 1‏
919 ‎‡a alzheimersdiseasethe2hithypothesis‏ ‎‡A Alzheimer's disease: the two-hit hypothesis‏ ‎‡9 1‏
919 ‎‡a amyloidbetaa‏ ‎‡A Amyloid-beta: a‏ ‎‡9 1‏
919 ‎‡a amyloidbetaalifepreserverforthebrain‏ ‎‡A Amyloid-beta: a (life) preserver for the brain‏ ‎‡9 1‏
919 ‎‡a amyloidbetaavascularsealantthatprotectsagainsthemorrhage‏ ‎‡A Amyloid-beta: a vascular sealant that protects against hemorrhage?‏ ‎‡9 1‏
919 ‎‡a amyloidbetaandtauserveantioxidantfunctionsintheagingandalzheimerbrain‏ ‎‡A Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain‏ ‎‡9 1‏
919 ‎‡a amyloidbetaderiveddiffusibleligandscauseimpairedaxonaltransportofmitochondriainneurons‏ ‎‡A Amyloid-beta-derived diffusible ligands cause impaired axonal transport of mitochondria in neurons‏ ‎‡9 1‏
919 ‎‡a amyloidbetainalzheimersdiseasethehorseorthecartpathogenicorprotective‏ ‎‡A Amyloid-beta in Alzheimer's disease: the horse or the cart? Pathogenic or protective?‏ ‎‡9 1‏
919 ‎‡a amyloidbetainducedtoxicityofprimaryneuronsisdependentupondifferentiationassociatedincreasesintauandcyclindependentkinase5expression‏ ‎‡A Amyloid-beta-induced toxicity of primary neurons is dependent upon differentiation-associated increases in tau and cyclin-dependent kinase 5 expression.‏ ‎‡9 1‏
919 ‎‡a amyloidbetataualterationsandmitochondrialdysfunctioninalzheimerdiseasethechickensortheeggs‏ ‎‡A Amyloid-beta, tau alterations and mitochondrial dysfunction in Alzheimer disease: the chickens or the eggs?‏ ‎‡9 1‏
919 ‎‡a amyloidbetathealternatehypothesis‏ ‎‡A Amyloid beta: the alternate hypothesis‏ ‎‡9 1‏
919 ‎‡a amyloidbetavaccinationtestingtheamyloidhypothesisheadswewintailsyoulose‏ ‎‡A Amyloid-beta vaccination: testing the amyloid hypothesis?: heads we win, tails you lose!‏ ‎‡9 1‏
919 ‎‡a amyloidbeta42interactsmainlywithinsolubleprionproteininthealzheimerbrain‏ ‎‡A Amyloid-beta42 interacts mainly with insoluble prion protein in the Alzheimer brain‏ ‎‡9 1‏
919 ‎‡a amyloidβ42interactsmainlywithinsolubleprionproteininthealzheimerbrain‏ ‎‡A Amyloid-β42 Interacts Mainly with Insoluble Prion Protein in the Alzheimer Brain‏ ‎‡9 1‏
919 ‎‡a amyloidsaggregatesandneuronalinclusionsgoodorbadnewsforneurons‏ ‎‡A Amyloids, Aggregates and Neuronal Inclusions: Good or Bad News for Neurons?‏ ‎‡9 1‏
919 ‎‡a amyotrophiclateralsclerosisanovelhypothesisinvolvingagainedlossoffunctioninthejnksapkpathway‏ ‎‡A Amyotrophic lateral sclerosis: a novel hypothesis involving a gained 'loss of function' in the JNK/SAPK pathway‏ ‎‡9 1‏
919 ‎‡a antibodiestopotatovirusybindtheamyloidbetapeptideimmunohistochemicalandnmrstudies‏ ‎‡A Antibodies to potato virus Y bind the amyloid beta peptide: immunohistochemical and NMR studies‏ ‎‡9 1‏
919 ‎‡a antigenantibodydissociationinalzheimerdiseaseanovelapproachtodiagnosis‏ ‎‡A Antigen-antibody dissociation in Alzheimer disease: a novel approach to diagnosis‏ ‎‡9 1‏
919 ‎‡a antigonadotropinsanovelstrategytohaltalzheimersdiseaseprogression‏ ‎‡A Antigonadotropins: a novel strategy to halt Alzheimer's disease progression‏ ‎‡9 1‏
919 ‎‡a antimicrobialpeptideβdefensin1expressionisupregulatedinalzheimersbrain‏ ‎‡A Antimicrobial peptide β-defensin-1 expression is upregulated in Alzheimer's brain‏ ‎‡9 1‏
919 ‎‡a antioxidantapproachesforthetreatmentofalzheimersdisease‏ ‎‡A Antioxidant approaches for the treatment of Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a antioxidantprotectionandneurodegenerativediseasetheroleofamyloidbetaandtau‏ ‎‡A Antioxidant protection and neurodegenerative disease: the role of amyloid-beta and tau.‏ ‎‡9 1‏
919 ‎‡a antioxidanttherapyinalzheimersdiseasetheoryandpractice‏ ‎‡A Antioxidant therapy in Alzheimer's disease: theory and practice‏ ‎‡9 1‏
919 ‎‡a apoptosisinalzheimerdiseaseamathematicalimprobability‏ ‎‡A Apoptosis in Alzheimer disease: a mathematical improbability‏ ‎‡9 1‏
919 ‎‡a apoptoticandoxidativeindicatorsinalzheimersdisease‏ ‎‡A Apoptotic and Oxidative Indicators in Alzheimer's Disease‏ ‎‡9 1‏
919 ‎‡a apoptoticpromotersandinhibitorsinalzheimersdiseasewhowinsout‏ ‎‡A Apoptotic promoters and inhibitors in Alzheimer's disease: Who wins out?‏ ‎‡9 1‏
919 ‎‡a ascorbatedistributionduringhibernationisindependentofascorbateredoxstate‏ ‎‡A Ascorbate distribution during hibernation is independent of ascorbate redox state‏ ‎‡9 1‏
919 ‎‡a assemblyinvitrooftauproteinanditsimplicationsinalzheimersdisease‏ ‎‡A Assembly in vitro of tau protein and its implications in Alzheimer's disease.‏ ‎‡9 1‏
919 ‎‡a atheroscleroticlesionsandmitochondriadnadeletionsinbrainmicrovesselsimplicationinthepathogenesisofalzheimersdisease‏ ‎‡A Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels: implication in the pathogenesis of Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a autophagocytosisofmitochondriaisprominentinalzheimerdisease‏ ‎‡A Autophagocytosis of mitochondria is prominent in Alzheimer disease‏ ‎‡9 1‏
919 ‎‡a autophagyinalzheimersdisease‏ ‎‡A Autophagy in Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a beyondestrogentargetinggonadotropinhormonesinthetreatmentofalzheimersdisease‏ ‎‡A Beyond estrogen: targeting gonadotropin hormones in the treatment of Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a biomarkersinalzheimersdiseasepastpresentandfuture‏ ‎‡A Biomarkers in Alzheimer's disease: past, present and future‏ ‎‡9 1‏
919 ‎‡a brca1maymodulateneuronalcellcyclereentryinalzheimerdisease‏ ‎‡A BRCA1 may modulate neuronal cell cycle re-entry in Alzheimer disease‏ ‎‡9 1‏
919 ‎‡a 100junphosphorylationinalzheimerdisease‏ ‎‡A c-Jun phosphorylation in Alzheimer disease‏ ‎‡9 1‏
919 ‎‡a callforelantopublishalzheimerstrialdetails‏ ‎‡A Call for Elan to publish Alzheimer's trial details.‏ ‎‡9 1‏
919 ‎‡a carnosineaversatileantioxidantandantiglycatingagent‏ ‎‡A Carnosine: a versatile antioxidant and antiglycating agent‏ ‎‡9 1‏
919 ‎‡a causesversuseffectstheincreasingcomplexitiesofalzheimersdiseasepathogenesis‏ ‎‡A Causes versus effects: the increasing complexities of Alzheimer's disease pathogenesis‏ ‎‡9 1‏
919 ‎‡a cd3inlewypathologydoestheabnormalrecallofneurodevelopmentalprocessesunderlieparkinsonsdisease‏ ‎‡A CD3 in Lewy pathology: does the abnormal recall of neurodevelopmental processes underlie Parkinson's disease‏ ‎‡9 1‏
919 ‎‡a cdk5isamajorregulatorofp38cascaderelevancetoneurotoxicityinalzheimersdisease‏ ‎‡A Cdk5 is a major regulator of p38 cascade: relevance to neurotoxicity in Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a cellcyclederegulationintheneuronsofalzheimersdisease‏ ‎‡A Cell cycle deregulation in the neurons of Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a cellcycleproteinsinalzheimersdiseaseplentyofwheelsbutnocycle‏ ‎‡A Cell cycle proteins in Alzheimer's disease: plenty of wheels but no cycle.‏ ‎‡9 1‏
919 ‎‡a cellcyclereentryandmitochondrialdefectsinmycmediatedhypertrophiccardiomyopathyandheartfailure‏ ‎‡A Cell cycle re-entry and mitochondrial defects in myc-mediated hypertrophic cardiomyopathy and heart failure‏ ‎‡9 1‏
919 ‎‡a cellcyclereentrymediatedneurodegenerationanditstreatmentroleinthepathogenesisofalzheimersdisease‏ ‎‡A Cell cycle re-entry mediated neurodegeneration and its treatment role in the pathogenesis of Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a cellularprionproteinisessentialforoligomericamyloidβinducedneuronalcelldeath‏ ‎‡A Cellular prion protein is essential for oligomeric amyloid-β-induced neuronal cell death‏ ‎‡9 1‏
919 ‎‡a cerebralamyloidangiopathymajorcontributorordecorativeresponsetoalzheimersdiseasepathogenesis‏ ‎‡A Cerebral amyloid angiopathy: major contributor or decorative response to Alzheimer's disease pathogenesis‏ ‎‡9 1‏
919 ‎‡a cerebralhemorrhageandamyloidbeta‏ ‎‡A Cerebral hemorrhage and amyloid-beta‏ ‎‡9 1‏
919 ‎‡a cerebrotendinousxanthomatosiscasereportwithevidenceofoxidativestress‏ ‎‡A Cerebrotendinous xanthomatosis: case report with evidence of oxidative stress‏ ‎‡9 1‏
919 ‎‡a challengingtheamyloidcascadehypothesissenileplaquesandamyloidbetaasprotectiveadaptationstoalzheimerdisease‏ ‎‡A Challenging the amyloid cascade hypothesis: senile plaques and amyloid-beta as protective adaptations to Alzheimer disease‏ ‎‡9 1‏
919 ‎‡a chapter19targetingoxidativemechanismsinalzheimerdisease‏ ‎‡A Chapter 19. Targeting Oxidative Mechanisms in Alzheimer Disease‏ ‎‡9 1‏
919 ‎‡a chapter5developmentofironchelatornanoparticleconjugatesaspotentialtherapeuticagentsforalzheimerdisease‏ ‎‡A Chapter 5 - Development of iron chelator-nanoparticle conjugates as potential therapeutic agents for Alzheimer disease‏ ‎‡9 1‏
919 ‎‡a chitinlikepolysaccharidesinalzheimersdiseasebrains‏ ‎‡A Chitin-like polysaccharides in Alzheimer's disease brains‏ ‎‡9 1‏
919 ‎‡a cholesterolhomeostasismarkersarelocalizedtomousehippocampalpyramidalandgranulelayers‏ ‎‡A Cholesterol homeostasis markers are localized to mouse hippocampal pyramidal and granule layers‏ ‎‡9 1‏
919 ‎‡a cholesteroloxidativestressandalzheimersdiseaseexpandingthehorizonsofpathogenesis‏ ‎‡A Cholesterol, oxidative stress, and Alzheimer's disease: expanding the horizons of pathogenesis‏ ‎‡9 1‏
919 ‎‡a chronicantioxidanttherapyreducesoxidativestressinamousemodelofalzheimersdisease‏ ‎‡A Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a chronicleptinsupplementationamelioratespathologyandimprovescognitiveperformanceinatransgenicmousemodelofalzheimersdisease‏ ‎‡A Chronic Leptin Supplementation Ameliorates Pathology and Improves Cognitive Performance in a Transgenic Mouse Model of Alzheimer's Disease‏ ‎‡9 1‏
919 ‎‡a chronicoxidativestresscausesincreasedtauphosphorylationinm17neuroblastomacells‏ ‎‡A Chronic oxidative stress causes increased tau phosphorylation in M17 neuroblastoma cells‏ ‎‡9 1‏
919 ‎‡a chronologicalprimacyofoxidativestressinalzheimerdisease‏ ‎‡A Chronological primacy of oxidative stress in Alzheimer disease.‏ ‎‡9 1‏
919 ‎‡a cleavageandconformationalchangesoftauproteinfollowphosphorylationduringalzheimersdisease‏ ‎‡A Cleavage and conformational changes of tau protein follow phosphorylation during Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a clinicalbenefitandpreservationofflavonolsindarkchocolatemanufacturing‏ ‎‡A Clinical benefit and preservation of flavonols in dark chocolate manufacturing‏ ‎‡9 1‏
919 ‎‡a clusterinupregulationfollowingsublethaloxidativestressandlipidperoxidationinhumanneuroblastomacells‏ ‎‡A Clusterin up-regulation following sub-lethal oxidative stress and lipid peroxidation in human neuroblastoma cells‏ ‎‡9 1‏
919 ‎‡a commentaryceramideandcholesterolpossibleconnectionsbetweennormalagingofthebrainandalzheimersdiseasejusthypothesesormolecularpathwaystobeidentifiedbyclaudiocostantinirekha1000kkolasaniandluigipuglielli‏ ‎‡A Commentary: "Ceramide and cholesterol: possible connections between normal aging of the brain and Alzheimer's disease. Just hypotheses or molecular pathways to be identified?" by Claudio Costantini, Rekha M.K. Kolasani, and Luigi Puglielli.‏ ‎‡9 1‏
919 ‎‡a comparativebiologyandpathologyofoxidativestressinalzheimerandotherneurodegenerativediseasesbeyonddamageandresponse‏ ‎‡A Comparative biology and pathology of oxidative stress in Alzheimer and other neurodegenerative diseases: beyond damage and response‏ ‎‡9 1‏
919 ‎‡a compensatoryresponsesinducedbyoxidativestressinalzheimerdisease‏ ‎‡A Compensatory responses induced by oxidative stress in Alzheimer disease‏ ‎‡9 1‏
919 ‎‡a contributionofredoxactiveironandcoppertooxidativedamageinalzheimerdisease‏ ‎‡A Contribution of redox-active iron and copper to oxidative damage in Alzheimer disease‏ ‎‡9 1‏
919 ‎‡a copperinducesapoptosisofneuroblastomacellsviaposttranslationalregulationoftheexpressionofbcl2familyproteinsandthetxmouseisabettermodelofhepaticthanbraincutoxicity‏ ‎‡A Copper Induces Apoptosis of Neuroblastoma Cells Via Post-translational Regulation of the Expression of Bcl-2-family Proteins and the tx Mouse is a Better Model of Hepatic than Brain Cu Toxicity‏ ‎‡9 1‏
919 ‎‡a coppermediatesdityrosinecrosslinkingofalzheimersamyloidbeta‏ ‎‡A Copper mediates dityrosine cross-linking of Alzheimer's amyloid-beta‏ ‎‡9 1‏
919 ‎‡a currentapproachesinthetreatmentofalzheimersdisease‏ ‎‡A Current approaches in the treatment of Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a declineinmitochondrialbioenergeticsunderliescentralinsulinresistanceinstreptozocininducedmodelofsporadicalzheimersdisease‏ ‎‡A Decline in mitochondrial bioenergetics underlies central insulin resistance in streptozocin-induced model of sporadic Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a dementiaandtestosteronelevelsinmen‏ ‎‡A Dementia and testosterone levels in men.‏ ‎‡9 1‏
919 ‎‡a detectionandlocalizationofmarkersofoxidativestressbyinsitumethodsapplicationinthestudyofalzheimerdisease‏ ‎‡A Detection and localization of markers of oxidative stress by in situ methods: application in the study of Alzheimer disease‏ ‎‡9 1‏
919 ‎‡a differentialregulationofglutamatereceptorsinalzheimersdisease‏ ‎‡A Differential regulation of glutamate receptors in Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a directandindirectrolesofcyclindependentkinase5asanupstreamregulatorinthe100junnh2terminalkinasecascaderelevancetoneurotoxicinsultsinalzheimersdisease‏ ‎‡A Direct and indirect roles of cyclin-dependent kinase 5 as an upstream regulator in the c-Jun NH2-terminal kinase cascade: relevance to neurotoxic insults in Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a dissociatedamyloidbetaantibodylevelsasaserumbiomarkerfortheprogressionofalzheimersdiseaseapopulationbasedstudy‏ ‎‡A Dissociated amyloid-beta antibody levels as a serum biomarker for the progression of Alzheimer's disease: a population-based study‏ ‎‡9 1‏
919 ‎‡a dissociatedaβantibodylevelinnewlydiagnosedalzheimersdiseaseapopulationbasedstudy‏ ‎‡A Dissociated Aβ antibody level in newly diagnosed Alzheimer's disease: A population-based study‏ ‎‡9 1‏
919 ‎‡a disturbanceinampactivatedproteinkinase‏ ‎‡A Disturbance in AMP-activated protein kinase‏ ‎‡9 1‏
919 ‎‡a disturbanceinampactivatedproteinkinaseampksignalingpathwayinalzheimersdisease‏ ‎‡A Disturbance in AMP-activated protein kinase (AMPK) signaling pathway in Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a divalentmetaltransporterironandparkinsonsdiseaseapathologicalrelationship‏ ‎‡A Divalent metal transporter, iron, and Parkinson's disease: a pathological relationship.‏ ‎‡9 1‏
919 ‎‡a dlp1dependentmitochondrialfragmentationmediates1methyl4phenylpyridiniumtoxicityinneuronsimplicationsforparkinsonsdisease‏ ‎‡A DLP1-dependent mitochondrial fragmentation mediates 1-methyl-4-phenylpyridinium toxicity in neurons: implications for Parkinson's disease‏ ‎‡9 1‏
919 ‎‡a dnadamageinducescdk2proteinlevelsandhistoneh2bphosphorylationinshsy5yneuroblastomacells‏ ‎‡A DNA damage induces cdk2 protein levels and histone H2B phosphorylation in SH-SY5Y neuroblastoma cells.‏ ‎‡9 1‏
919 ‎‡a downregulationofaminolevulinatesynthasetheratelimitingenzymeforhemebiosynthesisinalzheimersdisease‏ ‎‡A Down-regulation of aminolevulinate synthase, the rate-limiting enzyme for heme biosynthesis in Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a downregulationofserumgonadotropinsbutnotestrogenreplacementimprovescognitioninagedovariectomized3xtgadfemalemice‏ ‎‡A Down-regulation of serum gonadotropins but not estrogen replacement improves cognition in aged-ovariectomized 3xTg AD female mice‏ ‎‡9 1‏
919 ‎‡a downregulationofserumgonadotropinsisaseffectiveasestrogenreplacementatimprovingmenopauseassociatedcognitivedeficits‏ ‎‡A Down-regulation of serum gonadotropins is as effective as estrogen replacement at improving menopause-associated cognitive deficits‏ ‎‡9 1‏
946 ‎‡a b‏ ‎‡9 1‏
947 ‎‡a US‏ ‎‡9 1‏
996 ‎‡2 ISNI|0000000369306107
996 ‎‡2 DNB|1064907067
996 ‎‡2 RERO|A016603644
996 ‎‡2 PLWABN|9810543571905606
996 ‎‡2 DNB|137068352
996 ‎‡2 LC|no2016122970
996 ‎‡2 LC|n 83163851
996 ‎‡2 NUKAT|n 99001523
996 ‎‡2 BIBSYS|4014214
996 ‎‡2 LC|no2009192458
996 ‎‡2 NUKAT|n 2006055658
996 ‎‡2 LC|n 2004089966
996 ‎‡2 NSK|000335263
996 ‎‡2 NTA|338679057
996 ‎‡2 ISNI|000000002567802X
996 ‎‡2 BNF|14630383
996 ‎‡2 LIH|LNB:B_u__b_R;=B7
996 ‎‡2 BIBSYS|8052162
996 ‎‡2 SIMACOB|28210275
996 ‎‡2 CAOONL|ncf10055987
996 ‎‡2 BIBSYS|13028297
996 ‎‡2 LC|n 92806495
996 ‎‡2 BIBSYS|8030187
996 ‎‡2 PLWABN|9814302434005606
996 ‎‡2 LC|n 82225400
996 ‎‡2 ISNI|0000000123615540
996 ‎‡2 BNF|15523297
996 ‎‡2 LC|nb 97040039
996 ‎‡2 BIBSYS|90799252
996 ‎‡2 LC|no2023007759
996 ‎‡2 NLA|000054717891
996 ‎‡2 LC|nr2006009016
996 ‎‡2 BNC|981058616446606706
996 ‎‡2 NUKAT|n 2017182839
996 ‎‡2 NDL|01161394
996 ‎‡2 LC|n 87129323
996 ‎‡2 BIBSYS|10022339
996 ‎‡2 DNB|1082229725
996 ‎‡2 NUKAT|n 94300935
996 ‎‡2 DBC|87097969700594
996 ‎‡2 LC|n 83041295
996 ‎‡2 DNB|1043568972
996 ‎‡2 SUDOC|196546559
996 ‎‡2 LC|nb2001087414
996 ‎‡2 ISNI|0000000024557234
996 ‎‡2 NDL|01007223
996 ‎‡2 ISNI|0000000035421308
996 ‎‡2 LC|n 88254047
996 ‎‡2 LC|no2021120206
996 ‎‡2 PTBNP|106657
996 ‎‡2 BAV|495_300126
996 ‎‡2 PLWABN|9810631968305606
996 ‎‡2 LC|nr 96020312
996 ‎‡2 BNC|981058616445406706
996 ‎‡2 NTA|358180287
996 ‎‡2 LC|nb 98038558
996 ‎‡2 BIBSYS|90576088
996 ‎‡2 BNE|XX4775169
996 ‎‡2 PTBNP|31558
996 ‎‡2 LC|nb2013025955
996 ‎‡2 BNF|13340794
996 ‎‡2 ISNI|0000000512433417
996 ‎‡2 RERO|A023068041
996 ‎‡2 BIBSYS|90226720
996 ‎‡2 CAOONL|ncf13690061
996 ‎‡2 LC|no 98128170
996 ‎‡2 ISNI|0000000081058933
996 ‎‡2 ISNI|0000000117748734
996 ‎‡2 NUKAT|n 2023167183
996 ‎‡2 NII|DA05999469
996 ‎‡2 ISNI|000000038395926X
996 ‎‡2 ISNI|0000000024659038
996 ‎‡2 NSK|000392475
996 ‎‡2 NTA|40086178X
996 ‎‡2 NTA|06939153X
996 ‎‡2 RERO|A026407529
996 ‎‡2 CAOONL|ncf11055213
996 ‎‡2 NLR|RU NLR AUTH 7756974
996 ‎‡2 ISNI|0000000063050559
996 ‎‡2 BIBSYS|3040180
996 ‎‡2 NKC|mub2010614091
996 ‎‡2 ISNI|0000000048210518
996 ‎‡2 SUDOC|08171534X
996 ‎‡2 DNB|17402682X
996 ‎‡2 ISNI|0000000384199813
996 ‎‡2 BAV|495_54775
996 ‎‡2 LC|n 84134871
996 ‎‡2 ISNI|0000000443026227
996 ‎‡2 LIH|LNB:B1Z,;=BE
996 ‎‡2 NUKAT|n 2007096749
996 ‎‡2 ISNI|0000000110717265
996 ‎‡2 LC|n 2011046712
996 ‎‡2 SUDOC|033521298
996 ‎‡2 SUDOC|086814974
996 ‎‡2 DNB|1293409065
996 ‎‡2 CAOONL|ncf11312363
996 ‎‡2 LC|n 85047893
996 ‎‡2 SUDOC|087929384
996 ‎‡2 BNF|12431403
996 ‎‡2 ISNI|0000000416668814
996 ‎‡2 BNCHL|10000000000000000113813
996 ‎‡2 BNF|13597929
996 ‎‡2 ISNI|0000000418396963
996 ‎‡2 BNF|15558267
996 ‎‡2 ISNI|0000000036822859
996 ‎‡2 RERO|A025269234
996 ‎‡2 DNB|1024602877
996 ‎‡2 NKC|jx20100409007
996 ‎‡2 SUDOC|188040110
996 ‎‡2 NDL|00475270
996 ‎‡2 BIBSYS|90862526
996 ‎‡2 LC|no2016037191
996 ‎‡2 RERO|A012405199
996 ‎‡2 NUKAT|n 2005025213
996 ‎‡2 NUKAT|n 2002048812
996 ‎‡2 SUDOC|271808535
996 ‎‡2 BNF|14228316
996 ‎‡2 NTA|191682624
996 ‎‡2 NDL|001103919
996 ‎‡2 ISNI|0000000031461484
996 ‎‡2 J9U|987007329438705171
996 ‎‡2 SUDOC|26695975X
996 ‎‡2 BIBSYS|98072671
996 ‎‡2 SUDOC|11928507X
996 ‎‡2 BIBSYS|7014427
996 ‎‡2 LC|nb 99156730
996 ‎‡2 SUDOC|113753969
996 ‎‡2 LC|n 92071038
996 ‎‡2 ISNI|0000000114036512
996 ‎‡2 LC|no2015007017
996 ‎‡2 NII|DA11855361
996 ‎‡2 DNB|103546568X
996 ‎‡2 BNF|12458347
996 ‎‡2 J9U|987007426941805171
996 ‎‡2 ISNI|0000000508263726
996 ‎‡2 LC|nb2020003165
996 ‎‡2 BNC|981058616444806706
996 ‎‡2 LC|no2016168078
996 ‎‡2 ISNI|0000000115860669
996 ‎‡2 BIBSYS|90383626
996 ‎‡2 SUDOC|059363223
996 ‎‡2 NII|DA18322674
996 ‎‡2 BIBSYS|90816453
996 ‎‡2 BIBSYS|7055759
996 ‎‡2 NII|DA0883114X
996 ‎‡2 NII|DA03575020
996 ‎‡2 LC|no2024136945
996 ‎‡2 J9U|987007381334905171
996 ‎‡2 BAV|495_316089
996 ‎‡2 NII|DA07841024
996 ‎‡2 RERO|A005712237
996 ‎‡2 ISNI|0000000063624073
996 ‎‡2 LC|nb2008012359
996 ‎‡2 DNB|135506255
996 ‎‡2 SUDOC|085939013
996 ‎‡2 BNF|12017045
996 ‎‡2 LIH|LNB:8LF;=_t__j_
996 ‎‡2 CAOONL|ncf11499341
996 ‎‡2 DNB|1137198567
996 ‎‡2 BNC|981058616447106706
996 ‎‡2 ISNI|0000000081601414
996 ‎‡2 ISNI|0000000109016023
996 ‎‡2 ISNI|0000000046267561
996 ‎‡2 NTA|143930753
996 ‎‡2 LC|no2017073270
996 ‎‡2 BIBSYS|90652489
996 ‎‡2 LC|no2005104158
996 ‎‡2 LC|no2017154444
996 ‎‡2 LC|n 2016023550
996 ‎‡2 RERO|A013553352
996 ‎‡2 LC|n 88630455
996 ‎‡2 LC|no2013121510
996 ‎‡2 DNB|173182453
996 ‎‡2 ISNI|0000000052046319
996 ‎‡2 ISNI|0000000498898612
996 ‎‡2 CAOONL|ncf11312244
996 ‎‡2 ISNI|0000000074331647
996 ‎‡2 ISNI|0000000082498121
996 ‎‡2 SUDOC|120114097
996 ‎‡2 NUKAT|n 2012151345
996 ‎‡2 ISNI|0000000384916042
996 ‎‡2 CAOONL|ncf11196667
996 ‎‡2 LC|no2006135732
996 ‎‡2 BIBSYS|11026734
996 ‎‡2 BIBSYS|99004446
996 ‎‡2 DBC|87097919459314
996 ‎‡2 BIBSYS|90700677
996 ‎‡2 J9U|987007335711005171
996 ‎‡2 LC|n 96090520
996 ‎‡2 RERO|A009137220
996 ‎‡2 RERO|A003204519
996 ‎‡2 RERO|A003839679
996 ‎‡2 SUDOC|25842981X
996 ‎‡2 ISNI|0000000390740530
996 ‎‡2 BIBSYS|11074594
996 ‎‡2 ISNI|0000000384476796
996 ‎‡2 LC|no 98004579
996 ‎‡2 ISNI|0000000037108489
996 ‎‡2 BIBSYS|90387478
996 ‎‡2 ISNI|0000000026148485
996 ‎‡2 NII|DA11258715
996 ‎‡2 BIBSYS|90965281
996 ‎‡2 CAOONL|ncf12097282
996 ‎‡2 DNB|133069052
996 ‎‡2 DNB|1161749853
996 ‎‡2 BLBNB|000181406
996 ‎‡2 VLACC|000046376
996 ‎‡2 LC|n 88238165
996 ‎‡2 NUKAT|n 2024062246
996 ‎‡2 BIBSYS|10020233
996 ‎‡2 LC|nb2021004251
996 ‎‡2 ISNI|0000000085305364
996 ‎‡2 CAOONL|ncf11160211
996 ‎‡2 LC|n 93108326
996 ‎‡2 LC|n 77004568
996 ‎‡2 LC|n 80046200
996 ‎‡2 RERO|A011042512
996 ‎‡2 ISNI|0000000435023587
996 ‎‡2 LC|n 2005182352
996 ‎‡2 DNB|14204976X
996 ‎‡2 ISNI|0000000068377972
996 ‎‡2 NTA|175432147
996 ‎‡2 LC|no 95052676
996 ‎‡2 BNF|14635918
996 ‎‡2 NUKAT|n 2005130959
996 ‎‡2 BNF|15736984
996 ‎‡2 ISNI|0000000038742422
996 ‎‡2 NUKAT|n 01036583
996 ‎‡2 LNB|LNC10-000031504
996 ‎‡2 ISNI|000000003550850X
996 ‎‡2 SUDOC|272537519
996 ‎‡2 NKC|vse2007387330
996 ‎‡2 J9U|987007331006905171
996 ‎‡2 LC|n 94011533
996 ‎‡2 LC|n 79111477
996 ‎‡2 RERO|A003456942
996 ‎‡2 BIBSYS|90629150
996 ‎‡2 LC|no2015003925
996 ‎‡2 SUDOC|151772487
996 ‎‡2 ISNI|0000000509841145
996 ‎‡2 NII|DA11692132
996 ‎‡2 BNF|16951485
996 ‎‡2 BIBSYS|90544727
996 ‎‡2 DNB|124321488
996 ‎‡2 ISNI|0000000072485896
996 ‎‡2 ISNI|0000000051657177
996 ‎‡2 NKC|xx0158680
996 ‎‡2 RERO|A021963921
996 ‎‡2 LNB|LNC10-000030284
996 ‎‡2 NTA|303068973
997 ‎‡a 1965 2010 lived 0815 1219‏ ‎‡9 1‏
998 ‎‡a Smith‏ ‎‡b Mark A.‏ ‎‡2 BNF|15021893‏ ‎‡3 suggested‏ ‎‡3 exact title: (1.00, 'signaltransductioninalzheimersdisease', 'signaltransductioninalzheimersdisease')‏
998 ‎‡a Smith, Mark A.‏ ‎‡2 PLWABN|9810544659705606‏ ‎‡3 viafid‏ ‎‡3 exact title: (1.00, 'alzheimersdiseaseandthecellcycle', 'alzheimersdiseaseandthecellcycle')‏
998 ‎‡a Smith, Mark A.,‏ ‎‡2 LC|n 2013031838‏ ‎‡3 suggested‏ ‎‡3 double date‏
998 ‎‡a Mark Smith‏ ‎‡c American novelist, born 1935‏ ‎‡2 ISNI|0000000019415688‏ ‎‡3 suggested‏
998 ‎‡a Smith, Mark‏ ‎‡c (Analyst)‏ ‎‡2 ISNI|0000000019415688‏ ‎‡3 suggested‏
998 ‎‡a Smith, Mark‏ ‎‡2 ISNI|0000000019415688‏ ‎‡3 suggested‏
998 ‎‡a Smith, Mark‏ ‎‡c politologue‏ ‎‡2 ISNI|0000000019415688‏ ‎‡3 suggested‏
998 ‎‡a Smith, Mark A.‏ ‎‡2 NUKAT|n 2005130959‏ ‎‡3 suggested‏